New insights in ferroptosis: Potential therapeutic targets for the treatment of ischemic stroke

Abstract

Stroke is a common disease in clinical practice, which seriously endangers people’s physical and mental health. The neurovascular unit (NVU) plays a key role in the occurrence and development of ischemic stroke. Different from other classical types of cell death such as apoptosis, necrosis, autophagy, and pyroptosis, ferroptosis is an iron-dependent lipid peroxidation-driven new form of cell death. Interestingly, the function of NVU and stroke development can be regulated by activating or inhibiting ferroptosis. This review systematically describes the NVU in ischemic stroke, provides a comprehensive overview of the regulatory mechanisms and key regulators of ferroptosis, and uncovers the role of ferroptosis in the NVU and the progression of ischemic stroke. We further discuss the latest progress in the intervention of ferroptosis as a therapeutic target for ischemic stroke and summarize the research progress and regulatory mechanism of ferroptosis inhibitors on stroke. In conclusion, ferroptosis, as a new form of cell death, plays a key role in ischemic stroke and is expected to become a new therapeutic target for this disease.

Introduction

Stroke is a common disease in clinical practice, which seriously endangers people’s health and is mainly divided into two subtypes, including ischemic and hemorrhagic stroke (Peisker et al., 2017). Current evidence suggests that ischemic stroke accounts for approximately 85% of the morbidity of stroke (Benjamin et al., 2018), mainly due to cerebral blood circulation disorder, localized brain tissue necrosis or softening caused by ischemia and hypoxia, leading to corresponding nervous system function defects (Sacco et al., 2013). Ischemic stroke is also a serious disease with high mortality, and the resulting severe cognitive and motor impairments can significantly burden families and society (Owolabi et al., 2015; Donkor, 2018). The post-ischemic brain is characterized by the accumulation of amyloid plaques and neurofibrillary tangles, followed by the development of dementia (Yang et al., 2019). Therefore, ischemic stroke increases the neurological deficits in dementia patients (Owolabi et al., 2015).

It is widely thought that the neurovascular unit (NVU) plays a crucial role in the occurrence and development of ischemic stroke (Iadecola, 2017), as well as in the remodeling of blood vessels and nerves after stroke (Leigh et al., 2018). The past decade has witnessed significant inroads in pathological research on ischemic stroke with the discovery of a new form of cell death in the NVU of ischemic stroke, namely ferroptosis (Doll et al., 2017; Magtanong and Dixon, 2018; Zhou et al., 2021).

In recent years, ferroptosis has become a research hotspot (Dixon et al., 2012). During ferroptosis, a high abundance of unsaturated fatty acids on the cell membrane undergo lipid peroxidation under ferrous iron or ester oxygenase, thereby inducing cell death (Yang et al., 2016). The occurrence and execution of ferroptosis depend on the interaction of amino acid, lipid and iron metabolism (Ursini and Maiorino, 2020), and its sensitivity is also regulated by several key pathways and processes (Chen et al., 2021a). Ferroptosis is associated with various diseases such as Parkinson’s disease (Mahoney-Sanchez et al., 2021), tumor (Kim et al., 2016), and renal failure (Adedoyin et al., 2018), and the development of these diseases can be intervened by activating or inhibiting ferroptosis.

In ischemic stroke, pathological changes are closely related to ferroptosis, such as iron metabolism disorder, lipid peroxidation, and increased ROS (Hu et al., 2019; Ren et al., 2020). An increasing body of evidence from recently published studies substantiates the correlation between ferroptosis and stroke (Hu et al., 2019; Ren et al., 2020). This review provides a comprehensive overview of the NVU of ischemic stroke and the role of ferroptosis in ischemic stroke, providing new insights into the application of ferroptosis in treating ischemic stroke.

NVU in ischemic stroke

Although significant progress has been made in better understanding the mechanism of neuron injury and repair after ischemia (Figure 1), there is still a lack of effective treatment for this disease (Chan, 1996; Hu et al., 2017; Yang et al., 2017). In the past, research on cerebral ischemic injury was mostly limited to neurons (Yang et al., 2019) or different cell groups and structures in the brain (Yang et al., 2017; Qin et al., 2019), ignoring the integrity of brain function and the interaction between different structures. Recently, the concept of the neurovascular unit as a new protective target for ischemic brain injury has been proposed (Cai et al., 2017; Zhao et al., 2020a).

FIGURE 1

The neurovascular unit is mainly composed of neurons, glial cells (including astrocytes, microglia, oligodendrocytes), and the blood-brain barrier (BBB, including vascular endothelial cells, astrocytic end-foot processes, basal lamina and pericytes) to maintain homeostasis of the central system (Pardridge, 1991), and extracellular matrix that maintains the integrity of the brain tissue environment (Lo and Rosenberg, 2009; Iadecola, 2017). The NVU maintains the normal physiological function of neurons and the repair of damaged neurons, which emphasizes the importance of the interconnection and mutual influence between neurons, glial cells and cerebrovascular (Stamatovic et al., 2008; Lo and Rosenberg, 2009) and provides the foothold for further study of neuron injury and protection mechanism. Overall, the NVU plays a key role in the clinical treatment of ischemic stroke and is increasingly valued by researchers and clinicians (Iadecola, 2017).

Neurons

It is well-established that neurons are most vulnerable to cerebral ischemia-reperfusion injury (CIRI) (Lo and Rosenberg, 2009) and are continuously affected by several pathological reactions such as inflammation, excitatory amino acid toxicity, and oxidative stress after CIRI (Rohnert et al., 2012). Among them, excitatory amino acids include glutamate and aspartate (Brann and Mahesh, 1994), glutamate is the main excitatory neurotransmitter in the mammalian central nervous system, which can have long-term effects on the structure and function of neurons, and glutamate-mediated excitatory signal transduction can affect mammalian brain functions, including cognition, memory and learning. The release of a large number of excitatory amino acids will activate plenty of ion channels and lead to persistent intracellular Ca²⁺ level increase, cell damage and death, which is called excitatory amino acid toxicity (Gillessen et al., 2002). While, this excitotoxicity caused by excitatory amino acids is one of the earliest and widely recognized molecular mechanisms of CIRI (Lai et al., 2014). When the brain is in a state of ischemia and hypoxia, the release of excitatory neurotransmitters is increased and reuptake is impaired due to metabolic disorders, and eventually the level of excitatory neurotransmitters in the ischemic region increases rapidly that leads to aberrant activation of many Ca²⁺-dependent pathways and initiation of apoptosis, necroptosis and autophagy processes in the brain (Shen et al., 2022). Current evidence suggests that neuronal death accounts for the poor prognosis in ischemic stroke (Chen et al., 2020). Indeed, assessing the severity of an ischemic stroke and the cause of death depends largely on the number of neurons dying in the affected brain area (Lazarov and Hollands, 2016).

Microglia

Microglia are innate immune cells in the brain, accounting for approximately 5–20% of glial cells (Benveniste, 1997). The main functions of microglia are to recognize pathogens, phagocytose necrotic or apoptotic cells, remove damaged neurons, tissue fragments, small and inactive synapses, infected small molecules and macromolecules, regulate T cell response, and induce inflammatory process (Nimmerjahn et al., 2005). In addition, microglia have extensive connections with other NVU cells (Thurgur and Pinteaux, 2019), which can regulate the microenvironmental homeostasis of NVU, and have positive significance for maintaining the barrier function of BBB (Abdullahi et al., 2018). When an ischemic stroke occurs, neurons activate microglia to differentiate into M1-and M2-phenotypes by releasing certain soluble factors and intracellular components (Akhmetzyanova et al., 2019; Qin et al., 2019). It is well-established that M1-type microglia have a pro-inflammatory and deleterious effect on the ischemic brain (Yu et al., 2022), while M2-type microglia can reduce the inflammatory response and exert neuroprotective effects (Varin and Gordon, 2009; Soehnlein and Lindbom, 2010).

In addition, microglia can affect the activity of neurons by releasing ATP and stimulating astrocytes to release glutamate to increase the excitatory postsynaptic potential (Barakat and Redzic, 2016; Illes et al., 2021). After cerebral ischemia, microglia release many inflammatory factors (Soehnlein and Lindbom, 2010), destroy the normal function of neurons and damage vascular endothelial cells, thereby destroying the BBB structure and aggravating brain edema (Yenari et al., 2010).

Oligodendrocytes

Oligodendrocytes are the myelinating cells in the central nervous system (CNS) and originate from oligodendrocyte progenitor cells (OPCs). OPCs can differentiate into oligodendrocytes or astrocytes according to the environment (Hughes et al., 1988). Endothelial cells promote the proliferation of OPCs by releasing trophic factors such as brain-derived neurotrophic factor (BDNF) and basic fibroblast growth factor (bFGF) (Dugas et al., 2008) and release vascular endothelial growth factor A (VEGF-A) to promote oligodendrocyte migration (Guo et al., 2008; Arai and Lo, 2009). The main function of oligodendrocytes is to form an insulating myelin sheath wrapping the axons in the CNS, assist in the efficient transmission of bioelectrical signals, and maintain and protect the normal function of neurons (Baumann and Pham-Dinh, 2001; Kuhn et al., 2019). Abnormalities in oligodendrocytes not only lead to demyelinating lesions of the CNS but also cause neuronal damage, psychiatric diseases, and even brain tumors (Kuhn et al., 2019). Under ischemic conditions, the expression of Nogo-A in oligodendrocytes is upregulated (Kern et al., 2013), thereby inhibiting axonal remodeling, impairing neuronal function, and triggering the early breakdown of BBB by secreting matrix metalloproteinase-9 (Mandai et al., 1997; Dewar et al., 2003).

Vascular endothelial cells

Vascular endothelial cells (VECs) constitute a monolayer of specialized cells strategically positioned between the vascular wall and the bloodstream (Kruger-Genge et al., 2019). Ischemic stroke results from a combination of factors such as platelet adhesion and aggregation and related release reactions (Del Zoppo, 1998), fibrin protease activation, and fibrin formation after vascular endothelial injury (Zhou et al., 2020). Under normal conditions, certain active factors released by VECs play a protective role in regulating vascular tension, coagulation, fibrinolysis, and maintaining normal blood pressure and hemodynamics (Sandoo et al., 2010). Once the vascular endothelium is damaged, the exposed subendothelial layer can cause platelet adhesion and aggregation, leading to thrombosis (Chen and Lopez, 2005). The stimulated VECs can also release tissue factors to promote the extrinsic coagulation process involving coagulation factor XII and accelerate thrombosis (Lopes-Bezerra and Filler, 2003). Notably, prolonged ischemia-hypoxia and ischemia-reperfusion (I/R) can damage VECs (Zhou et al., 2020). In addition, ischemia and hypoxia can induce the expression of VEGF (Ramakrishnan et al., 2014), which can promote the proliferation of VECs and participate in angiogenesis, thereby suppressing ischemic stroke and playing a neuroprotective role (Lopes-Bezerra and Filler, 2003; Zhou et al., 2020).

Astrocytes

In glial cells, astrocytes perform multiple homeostatic functions to maintain the survival and stability of the NVU (Becerra-Calixto and Cardona-Gomez, 2017), exerting neuroprotective, angiogenic, immunomodulatory, neurogenic, and antioxidant effects with the ability to modulate synaptic function (Daneman and Prat, 2015; Becerra-Calixto and Cardona-Gomez, 2017). Under physiological conditions, astrocytes release various neurotrophic factors, which can repair damage to neurons and VECs (Ye et al., 2018). During cerebral ischemia, the energy supply of brain cells is insufficient, resulting in the dysregulation of intracellular calcium and sodium pumps (Peng et al., 2019). Because of the extensive gap junctions and hemichannels in astrocytes, the gap junctions are destroyed, and Ca²⁺ and toxic substances are rapidly transmitted, causing astrocytes to release a large amount of glutamate to aggravate the excitatory amino acid toxicity (Lim et al., 2021). On the other hand, astrocytes are overactivated in the acute phase of ischemia, eventually forming a glial scar that hinders the repair of neurons (Sofroniew, 2009).

Pericytes

Brain pericytes are located in the center of the NVU and respond by receiving, integrating and processing signals from neighboring cells (Hamilton et al., 2010; Armulik et al., 2011; Winkler et al., 2011). They are critical in maintaining the normal function of the CNS and are involved in the formation and maintenance of BBB, cerebral blood flow (CBF) regulation, immunoregulation, angiogenesis, and stability. Overwhelming evidence substantiates that the dysfunction and loss of pericytes play a key role in the pathogenesis of various cerebrovascular diseases (Winkler et al., 2011). It has been shown that after ischemia, pericytes begin to detach from the cerebral microvessels (Zhou et al., 2022), which causes the destruction of tight junctions between cells, resulting in the destruction and leakage of the BBB (Bergers and Song, 2005). The platelet-derived growth factor receptor β (PDGFRβ) on pericytes is upregulated after cerebral ischemia and can combine with PDGFβ secreted by VECs to promote the recruitment and migration of pericytes for neovascularization to promote maturation (Makihara et al., 2015; Hutter-Schmid and Humpel, 2016). It has been shown that pericytes begin to secrete VEGF within 24 h after ischemic stroke, which promotes angiogenesis in the peri-infarct area by activating VEGFR in endothelial cells (Shibuya, 2011; Yang et al., 2017; Zhou et al., 2022). Under ischemic and hypoxic conditions, pericytes can exhibit pluripotent stem cell properties and participate in immune responses (Davidoff, 2019; Fernandez-Morales et al., 2019). A recent study found that TNF-α could promote the release of IL-6 from pericytes, which contributed to the activation of microglia (Matsumoto et al., 2018a).

This NVU theory emphasizes the important connection between neurons, glial cells and microvessels after cerebral ischemia, corroborating that all components of NVU are involved in the pathological process of cerebral ischemia injury (Stamatovic et al., 2008; Mcconnell et al., 2017). This connection is realized through cell-cell and cell-matrix interaction. There are many chemicals involved in the regulation of BBB permeability in different cell types of NVU. These regulatory chemicals fall into different categories, such as proinflammatory cytokines (e.g., TNF-α, IL-1, IL-6), neurotransmitters (e.g., NO), ROS and other substances (Table 1). Comprehensive treatment of NVU can effectively combat ischemic stroke. Therefore, NVU provides a theoretical basis for the current research and treatment of neurological diseases, and targeting NVU from a global perspective may bring new opportunities for treating ischemic stroke.

Mechanisms and key regulators of ferroptosis

Programmed cell death plays an important role in homeostasis and disease development. Among them, ferroptosis is a newly discovered form first proposed by Stockwell et al., in 2012 (Dixon et al., 2012). Ferroptosis is significantly different from other types of cell death such as apoptosis, necrosis, autophagy, and pyroptosis at the morphological, biochemical, and genetic levels (Dixon et al., 2012). The morphological features of ferroptosis are mainly manifested in mitochondria, including reduced volume, increased membrane density, and reduced numbers or absence (Chen et al., 2021a; Jiang et al., 2021). Regarding biochemical characteristics, ferroptosis manifests as glutathione depletion, glutathione peroxidase 4 (GPX4) inactivation, and lipid peroxide accumulation (Chen et al., 2021a; Jiang et al., 2021).

It has been confirmed that ferroptosis is closely related to neurodegenerative diseases, tumors, cardiovascular and cerebrovascular diseases, and acute kidney injury (AKI) (Ward et al., 2014; Fang et al., 2019; Bao et al., 2021), and its inhibitors can effectively delay disease progression and improve clinical symptoms (Angeli et al., 2017). However, the regulatory mechanism of ferroptosis has not yet been fully elucidated. With significant progress achieved in the study of ferroptosis, various regulatory factors and mechanisms have been discovered, suggesting that it is mainly related to iron metabolism disorder, amino acid antioxidant system imbalance, and lipid peroxide accumulation (Figure 2) (Dixon et al., 2012; Chen et al., 2021a). When iron metabolism disorder causes the increase of intracellular free iron, iron catalyzes the production of ROS through the Fenton reaction, and ROS further promotes lipid peroxidation, causing the accumulation of lipid peroxides and inducing ferroptosis (Dixon et al., 2012; Stockwell et al., 2017; Chen et al., 2021a). Indeed, an in-depth study and elucidation of the pathophysiological mechanism of ferroptosis can provide new ideas and treatment methods for ferroptosis-related diseases.

FIGURE 2

Iron metabolism

Iron metabolism disorders, especially iron overload, are key to ferroptosis (Dixon et al., 2012). Fe³⁺ in the blood circulation is combined with transferrin and transported to the cell through transferrin receptor 1 (TFR1) on the cell membrane surface (Beguin et al., 2014). Then Fe³⁺ is reduced to Fe²⁺ and released into the labile iron pool (LIP) in the cytoplasm (Kakhlon and Cabantchik, 2002), while excess iron is stored in ferritin (Jacobs et al., 1972). During this process, nuclear receptor coactivator 4 (NCOA4) acts as an adaptor protein to mediate the targeted transport of ferritin to lysosomes for autophagic degradation, thereby releasing free Fe²⁺, a process called ferritinophagy, mainly responsible for iron release and recovery (Mancias et al., 2014). Part of Fe²⁺ is transported out of cells through ferroportin1 (FPN1) on the cell membrane to ensure that the intracellular iron concentration is not excessively high under physiological conditions (Zhang et al., 2011; Zhang et al., 2012). Current evidence suggests that iron metabolism disorders can increase intracellular LIP and cause an increase in intracellular free iron (Ravingerova et al., 2020).

Due to the instability and high reactivity of Fe²⁺, hydroxyl radicals can be generated through the Fenton reaction (Thomas et al., 2009), which can directly react with polyunsaturated fatty acids (PUFAs) in the plasma membrane to generate a large amount of lipid ROS (Magtanong et al., 2016), and further promote lipid peroxidation and peroxide accumulation, inducing cell ferroptosis (Stockwell et al., 2017).

System Xc⁻

The cystine-glutamate antiporter System Xc⁻ is widely distributed in the phospholipid bilayer of biological cells (Bannai, 1986; Sasaki et al., 2002; Bridges et al., 2012). It is a heterodimer composed of light chain solute carrier family seven member 11 (SLC7A11) and heavy chain solute carrier family three member 2 (SLC3A2) (Sato et al., 1999; Broer and Wagner, 2002; Verrey et al., 2004). The System Xc⁻ can export intracellular glutamate to the extracellular space while importing cystine into the cytoplasm, where cystine is reduced to cysteine, which is involved in glutathione (GSH) synthesis (Seib et al., 2011). Glutathione peroxidase (GPX), whose active center is selenocysteine, catalyzes the conversion of reduced GSH to oxidized glutathione (GSSG), converting toxic peroxides into hydroxyl compounds to protect cell membranes from oxidative stress damage (Guan et al., 2017).

GPX4 is the only enzyme found in the GPX family that can reduce peroxides in lipid membranes, and its antioxidant effect is significantly higher than other family members (Margis et al., 2008). In particular, GPX4 can degrade hydrogen peroxide and other small molecule peroxides induced by iron overload in cells, preventing ferroptosis caused by the accumulation of ROS (Borchert et al., 2018). The antioxidant activity of GPX4 depends on GSH, which acts as an electron donor and converts toxic lipid hydroperoxide into non-toxic lipid alcohol (L-OH) (Fei et al., 2020). When System Xc⁻ is blocked, glutamate and cystine cannot be exchanged, resulting in the accumulation of intracellular glutamate, decreased GSH synthesis and GPX4 activity, thereby increasing ROS in lipids and inducing cell ferroptosis (Forcina and Dixon, 2019).

Lipid peroxidation

Lipid peroxidation refers to the loss of hydrogen atoms of lipids under the action of free radicals or lipid peroxidase, resulting in the oxidation, fragmentation and shortening of lipid carbon chains and the production of lipid free radicals, lipid hydroperoxides (LOOH) and reactive aldehydes (such as malondialdehyde and 4-hydroxynonenal) and other cytotoxic substances, eventually cause lipid oxidative degradation reactions that damage cells (Ayala et al., 2014). ROS are a group of molecules with partially reduced oxygen, including peroxides, superoxides, singlet oxygen, free radicals, etc., which cause cell death by damaging DNA, RNA and lipid molecules (Su et al., 2019; Villalpando-Rodriguez and Gibson, 2021). As a member of intracellular ROS, lipid peroxides are the ultimate executors of ferroptosis (Cheng et al., 2021). The deleterious effect of lipid peroxidation is mainly reflected in the oxidative degradation of two important biofilm components, including phosphatidylethanolamines (PEs) and PUFAs (Gaschler and Stockwell, 2017).

PUFA is the main component of phospholipids in cell and organelle membranes and is also an important substrate for the synthesis of PE (Stubbs and Smith, 1984). PUFA has a high affinity for free radicals, and the hydrogen atoms between its double bonds are easily oxidized by free radicals (Cunnane, 1994). The lipid peroxidation reaction of PUFA is roughly divided into two stages (Kanner et al., 1987; Girotti, 1998; Ayala et al., 2014). First, ROS acquire hydrogen atoms in PUFA to generate lipid radicals (Yin et al., 2011); subsequently, lipid radicals interact with oxygen molecules to generate lipid peroxyl radicals (LOO-) (Chamulitrat and Mason, 1989). LOO- can reportedly abstract hydrogen atoms from other PUFAs to form lipid radicals and lipid hydroperoxides (Chamulitrat and Mason, 1989; Girotti, 1998). Moreover, LOO- participates in the oxidation process of PUFAs, which ensures that the lipid peroxidation of PUFAs exhibits the characteristics of a cascade reaction (Yin et al., 2011).

However, the affinity between PE and free radicals is not high, and oxidation sites need to be formed under the action of two enzymes before lipid peroxidation occurs (Pratt et al., 2011). First, long-chain acyl-Coa synthetase-4 (ACSL4) utilizes arachidonic acid (AA) and adrenic acid (AdA) to synthesize arachidonoyl-CoA (AA-COA) and adrenoyl-CoA (AdA-COA) (Ma et al., 2021); then, AA/AdA-COA combines with PE to form PE-AA/AdA under the catalytic action of lysophosphatidylcholine acyltransferase 3 (LPCAT3) (Kagan et al., 2017).

PE-AA/AdA is easily oxidized to cytotoxic PE-AA/AdA-OOH by free radicals or Arachidonate 15-Lipoxygenase (ALOX15), which promotes ferroptosis (Kagan et al., 2017). LOX-mediated lipid hydroperoxide production has been suggested to be involved in ferroptosis (Shintoku et al., 2017). The accumulation of lipid peroxides, especially phospholipid peroxides, is a hallmark event of ferroptosis (Shintoku et al., 2017). High levels of ACSL4 and LPCAT3 have been detected in various tumors, such as renal and liver cancer cells (Luo et al., 2021). At present, the expression of these two enzymes has been used to assess the sensitivity of various tumor cells to ferroptosis (Yuan et al., 2016a; Doll et al., 2017; Kagan et al., 2017; Magtanong and Dixon, 2018).

Nrf2

Nuclear factor-E2-related factor 2 (Nrf2) is a transcription factor with a leucine zipper structure, which plays a key anti-oxidation role (Jaiswal, 2004). The activity of Nrf2 is strictly regulated by Kelch-like ECH-associated protein 1 (Keap1) (Kobayashi and Yamamoto, 2006). Under normal conditions, Nrf2 binds to Keap1 and is inactivated with ubiquitination and degradation in the proteasome (Zhang et al., 2004). Once in a state of oxidative stress, Keap1 is degraded by autophagy to release Nrf2 (Kaspar et al., 2009). Free Nrf2 rapidly translocates to the nucleus, which binds to antioxidant response elements (AREs) in the promoter region to drive antioxidant gene expression, balance oxidative stress and maintain cellular redox homeostasis (Kwak et al., 2007).

It is well-established that Nrf2 can regulate a variety of antioxidant enzymes, such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPX), glutathione reductase (GR), NAD(P)H quinine oxidoreductase (NQO1) and so on (Dhakshinamoorthy et al., 2000; Zhu et al., 2005). Therefore, Nrf2 is considered an important regulator of ferroptosis and a therapeutic target for tumors and neurodegenerative diseases highly associated with oxidative stress (Abdalkader et al., 2018; Song and Long, 2020).

P53

p53 has attracted much interest as a tumor suppressor molecule since its discovery (Harris, 1996). The p53 molecule can induce apoptosis and cell cycle arrest, exerting a strong tumor suppressor effect (Chen, 2016). In 2015, Jiang et al. linked p53 to ferroptosis for the first time (Jiang et al., 2015) and demonstrated that mutation of p53 can inhibit the activity of System Xc⁻, downregulate the expression of SLC7A11 (Jiang et al., 2015), and reduce the activity of GPX4, thereby promoting lipid peroxidation and inducing ferroptosis (Jiang et al., 2015). It is widely thought that p53 is at the core of a powerful signaling network; it regulates the sensitivity of cells to ferroptosis in different cell types and under different stress factors through several independent signaling pathways (Harris and Levine, 2005; Huang, 2021).

In addition to increasing sensitivity to ferroptosis, p53 appears to have an opposing effect (Liu et al., 2020a). When cells undergo cysteine deprivation, another signaling pathway is activated, with increased expression of wild-type p53 to induce p21 transcription or inhibit DPP4 binding to NOX1, ultimately inhibiting cell susceptibility to ferroptosis (Wang et al., 2012; Badgley et al., 2020). These two functions seem contradictory, but they are unified in cells. On the one hand, ferroptosis, as a form of regulated cell death, has physiological significance in the evolution of species, and p53 can achieve the purpose of removing abnormal cells and inhibiting tumorigenesis by increasing the sensitivity of cells to ferroptosis (Jiang et al., 2015; Liu et al., 2020a); on the other hand, when metabolic stress occurs, p53 can reduce the sensitivity of cells to ferroptosis by enhancing the ability to regulate ROS level to help normal cells survive the damage induced by various stress factors and promote cell survival (Tarangelo et al., 2018). Overwhelming evidence substantiates that cell types and p53 mutation sites may influence the mechanism of p53 in regulating cell ferroptosis (Wynford-Thomas and Blaydes, 1998; Wang et al., 2008; Ji et al., 2022), although the specific underlying mechanism warrants further study.

FSP1

Previous studies suggested that GPX4 and free radical antioxidants regulate ferroptosis. Recently, Marcus Conrad and José Pedro Friedmann Angeli’s team used a clonal expression strategy to screen for genes that can inhibit ferroptosis caused by loss of GPX4 in human cancer cells and found that flavoprotein apoptosis-inducing factor mitochondria-related 2 (AIFM2) is an anti-ferroptosis gene and renamed AIFM2 to ferroptosis suppressor protein 1 (FSP1). FSP1, originally described as a pro-apoptotic gene, showed the ability to inhibit ferroptosis induced by GPX4 knockout (Doll et al., 2019). In addition, the researchers found that the main mechanism of FSP1 in inhibiting ferroptosis is to reduce Coenzyme Q₁₀ (CoQ₁₀) with NAD(P)H, inhibit lipid peroxidation, and resist the occurrence of ferroptosis (Doll et al., 2019). The FSP1-CoQ₁₀-NAD(P)H pathway exists as an independent parallel system, which, together with GPX4 and glutathione, inhibits phospholipid peroxidation and ferroptosis (Bersuker et al., 2019; Doll et al., 2019). Their anti-ferroptosis properties have been widely used in the study of anti-tumor therapy (Bersuker et al., 2019). Growing evidence suggests that when GPX4 is inactivated, FSP1 can continue to maintain tumor growth in vivo, while deletion of GPX4 and FSP1 can inhibit tumor growth (Doll et al., 2019). As a novel ferroptosis inhibitor, FSP1 provides a new direction for disease research.

ACSL4

ACSL4 is a lipid metabolism enzyme required for lipid peroxidation and belongs to the ACSL family (Lopes-Marques et al., 2013). Current research suggests that PUFAs can be used as substrates for lipid peroxidation (Ayala et al., 2014), and their accumulation is a marker of ferroptosis; thus, the intracellular PUFAs content determines the development of ferroptosis and increased content can promote the progression of lipid peroxidation-induced ferroptosis (Das, 2019; Kuang et al., 2020). ACSL4 can activate free PUFAs and then complete the peroxidation process of membrane phospholipids with the participation of the other key enzymes, LPCAT3 and ALOX15 (Lee et al., 2021). Therefore, the ACSL4/LPCAT3/ALOX15 pathway can promote lipid peroxidation-induced ferroptosis (Lee et al., 2021). Zhang et al. showed that PKCβII, one of the isoforms of PKC (Steinberg, 2008), is an important lipid peroxidation sensor activated by lipid peroxidation during ferroptosis that can phosphorylate ACSL4 to amplify the effect of lipid peroxidation, eventually inducing ferroptosis (Zhang et al., 2022). This study also confirmed that the PKCβII-ACSL4 mechanism affects the efficacy of cancer immunotherapy by regulating ferroptosis (Zhang et al., 2022).

Other regulatory mechanisms

Heat shock proteins (HSP) are a class of highly conserved molecular chaperones expressed in response to environmental stress and render cells resistant to different types of cell death (Feder and Hofmann, 1999). For example, HSPB1 can inhibit ferroptosis by reducing iron uptake (Sun et al., 2015); HSPA5 binds to and stabilizes GPX4, thereby indirectly avoiding the damage of lipid peroxidation in ferroptosis (Zhu et al., 2017); however, the HSP9 inhibitor CDDO can inhibit ferroptosis in tumor cells, suggesting that HSP90 may play a different role in ferroptosis (Qin et al., 2015).

Mitochondria have been reported to participate in the pathogenesis of ferroptosis (Gao et al., 2019). CDGSH iron-sulfur domain 1 (CISD1) is a class of mitochondrial iron-exporting proteins that inhibit ferroptosis by preventing the accumulation of iron and the production of ROS in mitochondria (Yuan et al., 2016b). In addition, voltage-dependent anion channels (VDACs) located in the mitochondrial outer membrane play an important regulatory role in ferroptosis (Lemasters, 2017). It has been shown that Erastin, a ferroptosis inducer (Shibata et al., 2019; Zhao et al., 2020b), can act on VDAC to promote the release of a large number of oxides, causing ROS-dependent mitochondrial dysfunction and bioenergy exhaustion to induce ferroptosis (Zhao et al., 2020b), while the reduction of VDAC expression can reduce the occurrence of Erastin-induced ferroptosis (Yang et al., 2020).

Epigenetics is a key factor in regulating gene expression, and more and more research results show that epigenetic regulation (e.g., DNA methylation, histone modification and miRNA) plays an important role in ferroptosis (Jaenisch and Bird, 2003; Wu et al., 2020). DNA methylation is the most widely studied epigenetic modification. Increased DNA methylation may lead to gene silencing, while decreased methylation activates gene expression (Newell-Price et al., 2000), and DNA methylation is closely related to iron metabolism and can control the expression of ferroptosis-related genes (e.g., GPX4 and SLC7A11) to regulate ferroptosis (Zhao et al., 2022). Currently, DNA methylation is widely used as a diagnostic, predictive, and prognostic biomarker for multiple cancers (Huo et al., 2019). According to the histone modification studies, it was found that reducing histone 2A ubiquitination (H2Aub) on the SLC7A11 promoter can downregulate SLC7A11 and prevent ferroptosis (Zhang et al., 2019a); the histone 2B monoubiquitination (H2Bub1) modification is significantly down-regulated during the induction of ferroptosis, and artificial inhibition of endogenous H2Bub1 can significantly increase the sensitivity of cells to the ferroptosis inducer Erastin (Wang et al., 2019); in addition, histone deacetylase (HDAC) can regulate iron metabolism by inhibiting HAMP gene expression (Sukiennicki et al., 2019). There are also many studies reporting that a large number of microRNAs (miRNAs) can regulate ROS metabolism and ferroptosis (Zhang et al., 2020a). Mitofusin (Mfn) is a key protein that maintains mitochondrial morphology, regulates cellular lipid metabolism, endoplasmic reticulum stress and ROS generation (Papanicolaou et al., 2011), and plays a potential role in ferroptosis (Wei et al., 2020). miR-195, miR-125a and miR-761 have all been reported to regulate the mitochondrial function and metabolism of breast cancer cells, pancreatic cancer cells and liver cancer cells by targeting Mfn2, respectively, and affect the growth of tumor cells (Guo et al., 2017; Pan et al., 2018; Purohit et al., 2019); miR-137 can negatively regulate ferroptosis by directly targeting glutamine transporter SLC1A5 in melanoma cells (Luo et al., 2018). These further reveal the miRNA regulation role in ferroptosis, which contributes to an in-depth understanding of the mechanism of ferroptosis.

Ferroptosis in ischemic stroke

An increasing body of evidence from recently published studies suggests that ferroptosis is closely related to various diseases, such as tumor and neurological diseases (Ward et al., 2014; Fang et al., 2019; Bao et al., 2021). On the one hand, ferroptosis inducers can induce ferroptosis in abnormal cells, and tumor cells are highly sensitive to ferroptosis (Wu et al., 2019). Accordingly, ferroptosis can be induced in tumor cells to treat tumors. Non-targeted strategies based on nanoparticles have been designed to deliver iron, peroxides and other toxic substances to kill tumor cells (Zhang et al., 2019b; Raj et al., 2021).

The discovery of various enzymes regulating ferroptosis has enabled the targeted therapy of tumors, the most prominent target being GPX4, which is expressed in most tumor cells and is important for cell survival (Zhang et al., 2020b). GPX4-deficient cancer cells can be efficiently eliminated by the FSP-specific inhibitor iFSP1, while in GPX4-expressing cancer cells, iFSP1 cooperates with RSL3 to induce cancer cell ferroptosis (Gaschler et al., 2018). Therefore, FSP1 inhibitors may have clinical applications, especially for treating drug-resistant tumors or tumors that exhibit de-differentiation characteristics (Wang et al., 2021a). In addition, pharmacological or genetic inhibition of system Xc⁻ to prevent the development and metastasis of various tumors has yielded good efficacy and low toxicity in mouse models (Zhu et al., 2019).

On the other hand, ferroptosis inhibitors can inhibit ferroptosis in normal cells and can be used to prevent or treat neurological diseases (Angeli et al., 2017). Studies have found that ferroptosis is associated with Parkinson’s disease (Mahoney-Sanchez et al., 2021). Ferroptosis is an important cell death pathway of dopaminergic neurons (Do Van et al., 2016), and the ferroptosis inhibitor ferrostatin-1 can reportedly inhibit neuronal cell death in vitro and in vivo (Reichert et al., 2020). Interestingly, it has been reported that many pathological features of Alzheimer’s disease are associated with an imbalance in iron homeostasis, and iron overload in the brain may be responsible for the rapid cognitive decline in Alzheimer’s patients (Belaidi and Bush, 2016). Water maze experiments showed that mice with GPX4 knockout in the cerebral cortex and hippocampal neurons showed significant cognitive impairment and degeneration of hippocampal neurons. The degree of neurodegeneration was reduced after treatment with Vitamin E or the ferroptosis inhibitor Liproxstatin-1 (Hambright et al., 2017; Lane et al., 2018). These studies suggest that ferroptosis is widely involved in regulating the functions of neurons related to learning and memory.

It has been established that the levels of intracellular lipid peroxides and Fe²⁺ are increased during stroke, and ferroptosis inhibitors can upregulate the levels of GSH, GPX4 or system Xc⁻ to alleviate brain damage, indicating that ferroptosis affects the progression of stroke (Magtanong and Dixon, 2018; Zhang et al., 2021b). Studies have shown that ferroptosis inhibitors protect mice from ischemia-reperfusion injury in a middle cerebral artery occlusion (MCAO) model (Tuo et al., 2017), suggesting that ferroptosis can lead to neuronal death and NVU damage after ischemic stroke (Xu et al., 2022). Understanding the roles of iron metabolism, amino acid metabolism, and lipid metabolism of ferroptosis in ischemic stroke provides theoretical support for treating this disease (Jiang et al., 2021). The following content specifically discusses the role of ferroptosis in ischemic stroke (Figure 3).

FIGURE 3

Iron metabolism and ischemic stroke

It is well-established that iron homeostasis in the brain is disrupted after ischemic stroke, which impedes NVU recovery (Hu and Song, 2017). Intracellular iron overload is the main mechanism for inducing ferroptosis after cerebral ischemia, and the inhibition of iron overload can suppress ferroptosis in ischemic stroke and reduce damage (Fang et al., 2018). Under pathological conditions of ischemia and hypoxia, the expression of ferritin, transferrin, and TFR1 in the brain is increased, resulting in increased iron uptake by neurons and oligodendrocytes in the NVU (Kawabata, 2019; Ng et al., 2019). The acidic environment of ischemia and hypoxia can cause the overexpression of divalent metal-ion transporter 1 (DMT1) in microglia (Rotin et al., 1986; Chang et al., 2006), resulting in increased brain iron content (Cheli et al., 2018); meanwhile, ischemia can upregulate TFR1 levels, resulting in increased iron uptake (Chen et al., 2019; Tang et al., 2021).

There is a rich literature available suggesting that serum hepcidin and iron concentrations are elevated in patients with ischemic stroke, indicating that hepcidin is critical in cerebral ischemic iron overload (Davalos et al., 1994; Petrova et al., 2016). During ischemic stroke, the expression of interleukin-6 (IL-6) in cells increases hepcidin through the JAK/STAT3 pathway (Cojocaru et al., 2009), which causes FPN1 degradation, resulting in reduced iron release and thus intensified iron accumulation in cells (Cojocaru et al., 2009; Zhou et al., 2017). Therefore, the rational application of iron metabolism inhibitors, such as deferoxamine and iron chelators, to reduce the iron content in the brain after an ischemic stroke can reduce neuronal death and promote the recovery of NVU function after ischemic stroke (Jones et al., 2020; Roemhild et al., 2021; Yang et al., 2021).

In 2017, Tuo et al. revealed the relationship between Tau and ferroptosis and the role of ferroptosis in CIRI using the MCAO mouse model (Tuo et al., 2017). Tau can promote neuronal iron efflux and inhibit ferroptosis, which may be related to the reduction of tau caused by cerebral ischemia. Meanwhile, ferroptosis inhibitors liproxstatin-1 (Lip-1) or ferrostatin-1 (Fer-1) can significantly reduce neurological damage, indicating that ferroptosis can aggravate CIRI.

After ischemic stroke, the BBB is destroyed, leading to cerebral edema and aggravating brain tissue damage and neurological dysfunction (Abdullahi et al., 2018). Numerous studies have shown that systemic iron pools are transferred to neurons in the brain parenchyma when the BBB is disrupted, thereby exacerbating ferroptosis. Accordingly, changes in iron content in brain tissue reflect the degree of BBB dysfunction (Degregorio-Rocasolano et al., 2019). Iron accumulation accompanies the entire pathological process, and iron metabolism is considered an important pathophysiological factor involved in secondary injury after ischemic stroke (Waldvogel-Abramowski et al., 2014; Roemhild et al., 2021).

Amino acid metabolism and ischemic stroke

As the brain’s most abundant excitatory neurotransmitter, glutamate is a critical regulator in maintaining neural function (Zhou and Danbolt, 2014). NVU damage and death caused by excessively high extracellular glutamate concentration is known as excitotoxicity (Yang et al., 2019). In ischemic stroke, when the brain is in a state of ischemia and hypoxia due to metabolic disorders, glutamate release is increased, and reuptake is hindered, resulting in a rapid increase in glutamate levels in the ischemic area of the brain (Castillo et al., 1996). Subsequent activation of glutamate receptors leads to abnormal activation of several signaling pathways and iron deposition to stimulate cell death (Griesmaier and Keller, 2012; Willard and Koochekpour, 2013). Therefore, glutamate excitotoxicity is widely thought to be one of the mechanisms of ferroptosis (Zhang et al., 2021c). Indeed, glutamate excitotoxicity after cerebral ischemia, described as ferroptosis, can be effectively suppressed by the ferroptosis inhibitor Fer-1 (Xie et al., 2022).

As mentioned above, system Xc⁻ has a positive effect on inhibiting ferroptosis; however, the increase of extracellular glutamate content caused by cerebral ischemia is mainly caused by system Xc⁻ (Ikeda et al., 1989), and inhibiting the expression of system Xc⁻ can hinder ferroptosis, thereby reducing cerebral ischemia damage (Vespa et al., 1998). Domercq et al. showed that system Xc⁻ was upregulated in astrocytes and microglia in a rat model of stroke, while its inhibition reduced inflammation and attenuated CIRI (Matute et al., 2006; Martin et al., 2018). It can be concluded that the increased expression of System Xc⁻ during cerebral ischemia does not inhibit but promote the occurrence of ferroptosis, which may be due to the upregulated expression of System Xc⁻, leading to the excitotoxic effect caused by glutamate release exceeding its own antioxidant protective effect (Polewski et al., 2016).

In addition, GSH, as an endogenous inhibitor of ferroptosis, is reportedly related to ischemic stroke (Zhang et al., 2021b). Enhancing the expression of GPX4 and GSH synthesis can inhibit ferroptosis and reduce ischemic stroke injury (Zhang et al., 2021b). Increased lipid peroxidation levels and decreased GSH levels have been detected in an MCAO model (Liu et al., 2020b). Moreover, Edaravone has been proposed to counteract ferroptosis in various conditions, especially in cystine deficiency leading to decreased GSH content, and has been clinically approved for the treatment of acute ischemic stroke (Kikuchi et al., 2009; Matsumoto et al., 2018b). In addition, selenium (Se) can effectively enhance and maintain the activity of GPX4 (Ferguson et al., 2012; Liu et al., 2021). After ischemic stroke, Se supplementation can effectively inhibit GPX4-dependent ferroptosis and endoplasmic reticulum (ER) stress-induced cell death and improve NVU function by promoting GPX4 expression (Alim et al., 2019). In recent years, much emphasis has been placed on understanding the direct effects of GPX4 and GSH on stroke.

Lipid metabolism and ischemic stroke

Lipid peroxidation is a key driver of ferroptosis, stimulated by oxidative stress (Lee et al., 2021). ROS can accumulate to toxic levels during oxidative stress, leading to cellular damage and dysfunction, whereas antioxidants can prevent cellular damage by converting ROS into harmless molecules (Conrad et al., 2018). ROS are produced in large quantities during ischemic stroke, along with decreased levels of endogenous antioxidants, leading to oxidative stress (Cadenas, 2018). For example, the 1,2,4-triazole derivative compound 11 can exert a neuroprotective effect by promoting the expression of Nrf2 and SOD to induce an antioxidant effect (Lao et al., 2022). During a stroke, AA and AdA on the cell membrane can generate lipid peroxides through a series of reactions (Mccall et al., 1987; Nishizawa et al., 2021). Growing evidence suggests that ACSL4 and LOX, especially 12/15-LOX, are increased in ischemic stroke (Jin et al., 2008; Singh and Rao, 2019).

LOX is a key enzyme that causes lipid peroxidation and induces ferroptosis (Shintoku et al., 2017). It has been reported that 12/15-Lox gene deletion can reduce the infarct size after stroke (Singh and Rao, 2019). Additionally, 12/15-LOX were highly expressed in a cerebral ischemia model, and their inhibitors could inhibit the damage of ferroptosis to NVU cells (Jin et al., 2008). For example, the specific inhibitor ML351 has been reported to exert a protective effect against CIRI (Tourki et al., 2021). Moreover, ACSL4 participates in the synthesis and remodeling of PEs, thus affecting the synthesis of lipid peroxides, and upregulation of its expression can contribute to ferroptosis (Kuwata et al., 2019). It has been shown that in ischemic stroke, ACSL4 is upregulated and mediates neuronal death, ultimately leading to stroke injury (Li et al., 2019). Moreover, the ACSL4 inhibitor rosiglitazone can inhibit ferroptosis and protect brain function (Li et al., 2019). Cui et al. found that knockout of ACSL4 protects mice from cerebral ischemia, whereas its overexpression can exacerbate brain damage (Cui et al., 2021). Other studies have found that the accumulation of Fe²⁺ and ROS decreased, the expression of ACSL4 and TFR decreased, and GPX4 and FTH1 increased in MCAO model cells treated with safflower flavin thus inhibiting neuronal ferroptosis in MCAO (Li et al., 2021).

These findings suggest that both ACSL4 and LOX involved in lipid metabolism can serve as innovative therapeutic targets for ischemic stroke (Cui et al., 2021), inhibiting ferroptosis by reducing ROS accumulation and lipid peroxidation, providing new ideas for the treatment of ischemic stroke (Li et al., 2021).

Additionally, mounting evidence suggests that Nrf2 is an important regulator of the cellular antioxidant defense system (Abdalkader et al., 2018), and its moderate activation is beneficial in alleviating cerebral ischemic injury (Lao et al., 2022). Although little evidence is available that changes in Nrf2 levels directly affect ferroptosis in stroke, several studies have suggested that the Nrf2 pathway can alleviate stroke injury (Shih et al., 2005; Liu et al., 2018; Lao et al., 2022). It has also been shown that Epicatechin can regulate oxidative stress through the Nrf2 pathway via penetrating the BBB, thus protecting against transient cerebral ischemic injury (Chang et al., 2014).

Treatment of ischemic stroke by targeting ferroptosis

With the gradual recognition of the role of ferroptosis in ischemic stroke, treating ischemic stroke by inhibiting ferroptosis has become a research hotspot. As the pathological stimulus signals of ischemic stroke, ischemia, hypoxia and hypertension can all lead to brain damage (Khoshnam et al., 2017), during which local brain tissue metabolism changes, such as the reduction of GSH, GPX4 and tau proteins, and the increase of lipoxygenase (LOX) and BBB permeability, specifically manifested as iron overload and the enhancement of lipid peroxidation, that boost the generation of ROS and ultimately trigger ferroptosis-related cell death (Magtanong and Dixon, 2018). In addition, the restoration of normal blood circulation after ischemic stroke for a period of time will lead to CIRI (Lo and Rosenberg, 2009). Cerebral ischemia-reperfusion will lead to the activation of a variety of cell death pathways, including ferroptosis (Chen et al., 2021b). The phenomenon of increased lipid peroxidation and increased intracellular iron levels contribute to amplify the cerebral oxidative stress and inflammatory response, that further aggravate neuronal injury during reperfusion. Therefore, ferroptosis mediates and aggravates ischemic stroke injury (Figure 4). Major therapeutic advances include ferroptosis inhibitors, iron homeostasis regulators, lipid peroxidation pathway inhibitors, and ROS generation inhibitors. Table 2 summarized some key factors related to regulating ferroptosis, as well as therapeutic reagents in stroke and their functional mechanisms.

FIGURE 4

Current evidence suggests that ferroptosis inhibitors Fer-1 or Lip-1 can effectively reduce brain damage after reperfusion in a mouse model of ischemic stroke (Tuo et al., 2017; Feng et al., 2019), and Edaravone can be used to treat patients with acute ischemic stroke (Enomoto et al., 2019; Kobayashi et al., 2019). Mechanistic studies have suggested that Edaravone can scavenge free radicals and inhibit lipid peroxidation, thereby inhibiting oxidative damage (Kikuchi et al., 2013). Moreover, the intravenous administration of Edaravone after I/R in rats prevented the progression of cerebral edema and cerebral infarction, alleviated the accompanying neurological symptoms, and inhibited delayed neuronal death (Watanabe et al., 2018). In recent years, iron chelation therapy has been shown to suppress ferroptosis in a CIRI model (Cappellini et al., 2006; Grignano et al., 2020). Deferoxamine (DFO), a high-affinity iron chelator with the ability to bind to free iron ions to form stable complexes that weaken the Fenton response, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of iron overload-related diseases (Hanson et al., 2009; Tevlin et al., 2021). The ferroptosis inhibitor deferoxamine, which also acts as an iron chelator, improved cognitive impairment after stroke in diabetic rats with MCAO (Hanson et al., 2009). In addition, CoQ₁₀ was found to possess beneficial effects in a rat MCAO model and improved the prognosis of neurological impairment in patients with acute ischemic stroke (Nasoohi et al., 2019). Therefore, as an endogenous lipid-soluble antioxidant, CoQ₁₀ can effectively inhibit lipid peroxidation and is expected to be a drug that hinders ferroptosis (Littarru and Tiano, 2007; Rizzardi et al., 2021). Another drug inhibiting ferroptosis during ischemic stroke is Se (Ramezani et al., 2021). Alim et al. found that Se supplementation activates GPX4 homeostatic transcription in vivo, inhibiting cellular ferroptosis and improving neurological function (Alim et al., 2019). Octreotide has anti-inflammatory and antioxidant effects and protects the brain from cerebral ischemic injury by activating the Nrf2/ARE pathway (Wang et al., 2015). In patients with cerebral ischemic injury, melatonin has been reported to reduce nerve cell ferroptosis by increasing Nrf2, and significantly improve the learning, memory and cognitive abilities (Koh, 2008).

Intriguingly, several traditional Chinese herbal medicines have also been shown to inhibit ferroptosis in ischemic stroke. The monoterpenoid phenol carvacrol has been reported to effectively reduce ROS expression, reduce iron deposition and elevate GPX4 levels, thereby protecting hippocampal neurons from CIRI (Friedman, 2014; Li et al., 2016). Galangin inhibition of ferroptosis by activating SLC7A11/GPX4 can reportedly attenuate CIRI (Guan et al., 2021). In addition, Naotaifang extract has been reported to inhibit neuronal ferroptosis by downregulating TFR1/DMT1 and upregulating the SCL7A11/GPX4 pathway, thereby improving neurological function in post-ischemic rats (Lan et al., 2020).

Although these traditional Chinese medicines have not been clinically validated to improve the condition of ischemic stroke patients, their safety and lack of toxicity may facilitate their clinical translation (Fung and Linn, 2015).

Outlook

Ischemic stroke is a common disease that seriously endangers human health, and its incidence has increased in recent years (Sacco et al., 2013). Its complex pathological process and related mechanisms have become a research hotspot (Peisker et al., 2017; Yang et al., 2019). Thrombolytic therapy for cerebral ischemic injury has been limited by the narrow therapeutic time window, CIRI induction, and a high risk of hemorrhagic transformation, emphasizing the need for new treatments (Ringleb et al., 2002; Schellinger and Warach, 2004).

As the concept of NVU was proposed, researchers began to assess the feasibility of treating ischemic stroke from multiple approaches and perspectives (Cai et al., 2017; Zhao et al., 2020a). Stroke caused by different causes was regarded as a reactive injury process involving brain NVU (Yenari et al., 2010; Hu et al., 2017; Iadecola, 2017). In the treatment after brain injury, it has been transformed from single neuron protection to more comprehensive and in-depth protection of NVU (Wang et al., 2021b). The pathophysiological changes of NVU are typically characterized by tissue hypoxia, inflammation, activation of angiogenesis, and complex interactions between various components of NVU, which together lead to increased BBB permeability, brain edema, neuronal dysfunction and injury (Stanimirovic and Friedman, 2012). Cerebral ischemic injury is an inflammatory stimulus response, and all cellular components and matrix components of NVU are involved and make related responses (Ishikawa et al., 2004). The research and development of traditional drugs is limited to a certain pathological link in the pathological process of NVU, so the effect is not ideal. Therefore, during the treatment, the overall structure of NVU should be targeted, and the dynamic changes of each component should be coordinated to reduce nerve damage and promote repair. Ferroptosis is a new cell death mode discovered in recent years, with the continuous research, it has been recognized that ferroptosis plays an important role in a wide range of biological processes, including normal physiology and various pathological conditions (Stockwell et al., 2017). At present, the morphology, biology, and mechanism pathways of ferroptosis are partially understood, but the process of ferroptosis involves a variety of mechanisms, which are precisely regulated by signaling pathways. Questions remain as to how ferroptosis is related to the occurrence of diseases and whether it is associated with other modes of cell death to mediate the progression of diseases. Therefore, further in-depth study of the mechanism of ferroptosis and its role in different disease types is of great significance for finding therapeutic targets for related diseases and the development of targeted drugs.

The pathogenesis of ischemic stroke is complicated, current evidence suggests that ferroptosis plays an important role in the progression of ischemic stroke, inhibiting ferroptosis can alleviate ischemic stroke injury (Li et al., 2019; Liu et al., 2020b; Zhang et al., 2021b). When ischemic stroke occurs, iron ion aggregation in neurons leads to iron overload, which causes ROS aggregation through Fenton reaction, and GSH level is significantly reduced and lipid peroxidation increase in ischemic stroke mouse model (Liu et al., 2020b), indicating that ferroptosis is also a way of neurons death during the pathophysiological process of ischemic stroke. Ferroptosis inhibitors and iron chelators can effectively reduce the damage of neurons during ischemic brain death, suggesting that there are potential targets in the ferroptosis pathway to regulate ischemic stroke and its inhibition during ischemia has huge prospects for clinical application (Zhou et al., 2021).

However, investigating the role of ferroptosis in ischemic stroke is still in its preliminary stages, and many questions remain to be answered. For example, during ischemia and hypoxia, different cell types of NVU in brain tissue (Wang et al., 2021b), including neurons, microglia, astrocytes, oligodendrocytes, etc., are stimulated and damaged (Cai et al., 2017), and ferroptosis occurs in these different cell types, although its role remains to be elucidated (Doll et al., 2017; Jiang et al., 2021; Lee et al., 2021; Nishizawa et al., 2021), warranting further studies. In the field of basic research, there is a lack of effective biomarkers for ferroptosis, such as caspase activation in apoptosis or autolysosome formation in autophagy (Earnshaw et al., 1999; Hundeshagen et al., 2011). Accordingly, exploring specific biomarkers of ferroptosis is urgent. Over the years, studies of the molecular mechanisms of ferroptosis in ischemic stroke have mostly focused on cell and animal models, indicating that more clinical studies on patients with ischemic stroke are required. In addition, drug development targeting ferroptosis in ischemic stroke is an important aspect of research. Among the ferroptosis inhibitors, only one drug, Edaraavone, is used to treat patients with acute ischemic stroke (Enomoto et al., 2019; Kobayashi et al., 2019). Other drugs have been found to be effective in animal and cell models of stroke (Hanson et al., 2009; Narayan et al., 2021). Therefore, there is an urgent need to develop and validate effective drugs in clinical treatment, including traditional Chinese medicine.

Although ferroptosis, as a new mode of cell death, plays a key role in ischemic stroke and is expected to become a new therapeutic target to improve the outcomes of this patient population, ischemic stroke is regulated by a variety of cell death pathways. Both ferroptosis and other programmed cell death modes (including cell apoptosis, necroptosis and autophagy) play an important role in the pathological process of ischemic stroke. More and more evidence has shown that there are interacting signaling pathways between these cell death modes with similar initial signals and molecular regulators. For example, p53, not only induces apoptosis, but also regulates ferroptosis (Hong et al., 2017). In the relationship between ferroptosis and necroptosis, iron overload leads to the opening of the mitochondrial permeability transition pore (MPTP), which exacerbates RIP1 phosphorylation and leads to cell necroptosis (Tian et al., 2020); HSP90 induces necroptosis and ferroptosis by promoting RIP1 phosphorylation and inhibiting GPX4 activation (Wang et al., 2018). In addition, research have shown that ferroptosis is an autophagic cell death process (Gao et al., 2016). Knockdown of autophagy-related Atg5 and Atg7 genes can limit Erastin-induced ferroptosis by reducing intracellular iron and lipid peroxidation, and knockdown of NCOA4 can inhibit ferritin degradation and prevent ferroptosis (Lu et al., 2017), however, the specific mechanism of autophagy mediated ferroptosis needs to be further explored. This evidence suggests a strong crosslink between them, combination therapy targeting different cell death pathways may be the most effective strategy for the treatment of ischemic stroke.

References

• 1

  AbdalkaderM.LampinenR.KanninenK. M.MalmT. M.LiddellJ. R. (2018). Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. Front. Neurosci.12, 466. 10.3389/fnins.2018.00466

  • CrossRef
  • Google Scholar

• 2

  AbdullahiW.TripathiD.RonaldsonP. T. (2018). Blood-brain barrier dysfunction in ischemic stroke: Targeting tight junctions and transporters for vascular protection. Am. J. Physiol. Cell Physiol.315 (3), C343–C356. 10.1152/ajpcell.00095.2018

  • CrossRef
  • Google Scholar

• 3

  AdedoyinO.BodduR.TraylorA.LeverJ. M.BolisettyS.GeorgeJ. F.et al (2018). Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells. Am. J. Physiol. Ren. Physiol.314 (5), F702–F714. 10.1152/ajprenal.00044.2017

  • CrossRef
  • Google Scholar

• 4

  AkhmetzyanovaE.KletenkovK.MukhamedshinaY.RizvanovA. (2019). Different approaches to modulation of microglia phenotypes after spinal cord injury. Front. Syst. Neurosci.13, 37. 10.3389/fnsys.2019.00037

  • CrossRef
  • Google Scholar

• 5

  AlimI.CaulfieldJ. T.ChenY.SwarupV.GeschwindD. H.IvanovaE.et al (2019). Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke. Cell177 (5), 1262–1279. 10.1016/j.cell.2019.03.032

  • CrossRef
  • Google Scholar

• 6

  AngeliJ. P. F.ShahR.PrattD. A.ConradM. (2017). Ferroptosis inhibition: Mechanisms and opportunities. Trends Pharmacol. Sci.38 (5), 489–498. 10.1016/j.tips.2017.02.005

  • CrossRef
  • Google Scholar

• 7

  AnilkumarU.KhachoM.CuillerierA.HarrisR.PattenD. A.BilenM.et al (2020). MCL-1(Matrix) maintains neuronal survival by enhancing mitochondrial integrity and bioenergetic capacity under stress conditions. Cell Death Dis.11 (5), 321. 10.1038/s41419-020-2498-9

  • CrossRef
  • Google Scholar

• 8

  AraiK.LoE. H. (2009). An oligovascular niche: Cerebral endothelial cells promote the survival and proliferation of oligodendrocyte precursor cells. J. Neurosci.29 (14), 4351–4355. 10.1523/JNEUROSCI.0035-09.2009

  • CrossRef
  • Google Scholar

• 9

  ArmulikA.GenoveG.BetsholtzC. (2011). Pericytes: Developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell21 (2), 193–215. 10.1016/j.devcel.2011.07.001

  • CrossRef
  • Google Scholar

• 10

  AwoodaH. A.LutfiM. F.ShararaG. G.SaeedA. M. (2015). Oxidative/nitrosative stress in rats subjected to focal cerebral ischemia/reperfusion. Int. J. Health Sci.9 (1), 17–24. 10.12816/0024679

  • CrossRef
  • Google Scholar

• 11

  AyalaA.MunozM. F.ArguellesS. (2014). Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev.2014, 360438. 10.1155/2014/360438

  • CrossRef
  • Google Scholar

• 12

  BadgleyM. A.KremerD. M.MaurerH. C.DelGiornoK. E.LeeH. J.PurohitV.et al (2020). Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science368 (6486), 85–89. 10.1126/science.aaw9872

  • CrossRef
  • Google Scholar

• 13

  BannaiS. (1986). Exchange of cystine and glutamate across plasma membrane of human fibroblasts. J. Biol. Chem.261 (5), 2256–2263. 10.1016/s0021-9258(17)35926-4

  • CrossRef
  • Google Scholar

• 14

  BaoW. D.PangP.ZhouX. T.HuF.XiongW.ChenK.et al (2021). Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer's disease. Cell Death Differ.28 (5), 1548–1562. 10.1038/s41418-020-00685-9

  • CrossRef
  • Google Scholar

• 15

  BarakatR.RedzicZ. (2016). The role of activated microglia and resident macrophages in the neurovascular unit during cerebral ischemia: Is the jury still out?Med. Princ. Pract.25, 3–14. 10.1159/000435858

  • CrossRef
  • Google Scholar

• 16

  BaumannN.Pham-DinhD. (2001). Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev.81 (2), 871–927. 10.1152/physrev.2001.81.2.871

  • CrossRef
  • Google Scholar

• 17

  Becerra-CalixtoA.Cardona-GomezG. P. (2017). The role of astrocytes in neuroprotection after brain stroke: Potential in cell therapy. Front. Mol. Neurosci.10, 88. 10.3389/fnmol.2017.00088

  • CrossRef
  • Google Scholar

• 18

  BeguinY.AaproM.LudwigH.MizzenL.OsterborgA. (2014). Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis--a critical review. Crit. Rev. Oncol. Hematol.89 (1), 1–15. 10.1016/j.critrevonc.2013.10.008

  • CrossRef
  • Google Scholar

• 19

  BelaidiA. A.BushA. I. (2016). Iron neurochemistry in alzheimer's disease and Parkinson's disease: Targets for therapeutics. J. Neurochem.139, 179–197. 10.1111/jnc.13425

  • CrossRef
  • Google Scholar

• 20

  BenjaminE. J.ViraniS. S.CallawayC. W.ChamberlainA. M.ChangA. R.ChengS.et al (2018). Heart disease and stroke statistics-2018 update: A report from the American heart association. Circulation137 (12), e67–e492. 10.1161/CIR.0000000000000558

  • CrossRef
  • Google Scholar

• 21

  BenvenisteE. N. (1997). Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med.75 (3), 165–173. 10.1007/s001090050101

  • CrossRef
  • Google Scholar

• 22

  BergersG.SongS. (2005). The role of pericytes in blood-vessel formation and maintenance. Neuro. Oncol.7 (4), 452–464. 10.1215/S1152851705000232

  • CrossRef
  • Google Scholar

• 23

  BersukerK.HendricksJ. M.LiZ.MagtanongL.FordB.TangP. H.et al (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature575 (7784), 688–692. 10.1038/s41586-019-1705-2

  • CrossRef
  • Google Scholar

• 24

  BonnansC.ChouJ.WerbZ. (2014). Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol.15 (12), 786–801. 10.1038/nrm3904

  • CrossRef
  • Google Scholar

• 25

  BorchertA.KalmsJ.RothS. R.RademacherM.SchmidtA.HolzhutterH. G.et al (2018). Crystal structure and functional characterization of selenocysteine-containing glutathione peroxidase 4 suggests an alternative mechanism of peroxide reduction. Biochim. Biophys. Acta. Mol. Cell Biol. Lipids1863 (9), 1095–1107. 10.1016/j.bbalip.2018.06.006

  • CrossRef
  • Google Scholar

• 26

  BrannD. W.MaheshV. B. (1994). Excitatory amino acids: Function and significance in reproduction and neuroendocrine regulation. Front. Neuroendocrinol.15 (1), 3–49. 10.1006/frne.1994.1002

  • CrossRef
  • Google Scholar

• 27

  BridgesR. J.NataleN. R.PatelS. A. (2012). System xc(-) cystine/glutamate antiporter: An update on molecular pharmacology and roles within the CNS. Br. J. Pharmacol.165 (1), 20–34. 10.1111/j.1476-5381.2011.01480.x

  • CrossRef
  • Google Scholar

• 28

  BroerS.WagnerC. A. (2002). Structure-function relationships of heterodimeric amino acid transporters. Cell biochem. Biophys.36 (2-3), 155–168. 10.1385/CBB:36:2-3:155

  • CrossRef
  • Google Scholar

• 29

  CadenasS. (2018). ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic. Biol. Med.117, 76–89. 10.1016/j.freeradbiomed.2018.01.024

  • CrossRef
  • Google Scholar

• 30

  CaiW.ZhangK.LiP.ZhuL.XuJ.YangB.et al (2017). Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect. Ageing Res. Rev.34, 77–87. 10.1016/j.arr.2016.09.006

  • CrossRef
  • Google Scholar

• 31

  CappelliniM. D.CohenA.PigaA.BejaouiM.PerrottaS.AgaogluL.et al (2006). A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood107 (9), 3455–3462. 10.1182/blood-2005-08-3430

  • CrossRef
  • Google Scholar

• 32

  CastilloJ.DavalosA.NaveiroJ.NoyaM. (1996). Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke27 (6), 1060–1065. 10.1161/01.str.27.6.1060

  • CrossRef
  • Google Scholar

• 33

  CekanaviciuteE.BuckwalterM. S. (2016). Astrocytes: Integrative regulators of neuroinflammation in stroke and other neurological diseases. Neurotherapeutics13 (4), 685–701. 10.1007/s13311-016-0477-8

  • CrossRef
  • Google Scholar

• 34

  ChamulitratW.MasonR. P. (1989). Lipid peroxyl radical intermediates in the peroxidation of polyunsaturated fatty acids by lipoxygenase. J. Biol. Chem.264 (35), 20968–20973. 10.1016/s0021-9258(19)30031-6

  • CrossRef
  • Google Scholar

• 35

  ChanP. H. (1996). Role of oxidants in ischemic brain damage. Stroke27 (6), 1124–1129. 10.1161/01.str.27.6.1124

  • CrossRef
  • Google Scholar

• 36

  ChangY. Z.KeY.DuJ. R.HalpernG. M.HoK. P.ZhuL.et al (2006). Increased divalent metal transporter 1 expression might be associated with the neurotoxicity of L-DOPA. Mol. Pharmacol.69 (3), 968–974. 10.1124/mol.105.017756

  • CrossRef
  • Google Scholar

• 37

  ChangC. F.ChoS.WangJ. (2014). (-)-Epicatechin protects hemorrhagic brain via synergistic Nrf2 pathways. Ann. Clin. Transl. Neurol.1 (4), 258–271. 10.1002/acn3.54

  • CrossRef
  • Google Scholar

• 38

  CheliV. T.Santiago GonzalezD. A.MarzialiL. N.ZamoraN. N.GuitartM. E.SpreuerV.et al (2018). The divalent metal transporter 1 (DMT1) is required for iron uptake and normal development of oligodendrocyte progenitor cells. J. Neurosci.38 (43), 9142–9159. 10.1523/JNEUROSCI.1447-18.2018

  • CrossRef
  • Google Scholar

• 39

  ChenJ.LopezJ. A. (2005). Interactions of platelets with subendothelium and endothelium. Microcirculation12 (3), 235–246. 10.1080/10739680590925484

  • CrossRef
  • Google Scholar

• 40

  ChenJ. (2016). The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb. Perspect. Med.6 (3), a026104. 10.1101/cshperspect.a026104

  • CrossRef
  • Google Scholar

• 41

  ChenC.LiuP.DuanX.ChengM.XuL. X. (2019). Deferoxamine-induced high expression of TfR1 and DMT1 enhanced iron uptake in triple-negative breast cancer cells by activating IL-6/PI3K/AKT pathway. Onco. Targets. Ther.12, 4359–4377. 10.2147/OTT.S193507

  • CrossRef
  • Google Scholar

• 42

  ChenY. C.MaN. X.PeiZ. F.WuZ.Do-MonteF. H.KeefeS.et al (2020). A NeuroD1 AAV-based gene therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion. Mol. Ther.28 (1), 217–234. 10.1016/j.ymthe.2019.09.003

  • CrossRef
  • Google Scholar

• 43

  ChenX.LiJ.KangR.KlionskyD. J.TangD. (2021). Ferroptosis: Machinery and regulation. Autophagy17 (9), 2054–2081. 10.1080/15548627.2020.1810918

  • CrossRef
  • Google Scholar

• 44

  ChenY.FanH.WangS.TangG.ZhaiC.ShenL. (2021). Ferroptosis: A novel therapeutic target for ischemia-reperfusion injury. Front. Cell Dev. Biol.9, 688605. 10.3389/fcell.2021.688605

  • CrossRef
  • Google Scholar

• 45

  ChengY.SongY.ChenH.LiQ.GaoY.LuG.et al (2021). Ferroptosis mediated by lipid reactive oxygen species: A possible causal link of neuroinflammation to neurological disorders. Oxid. Med. Cell. Longev.2021, 5005136. 10.1155/2021/5005136

  • CrossRef
  • Google Scholar

• 46

  CojocaruI. M.CojocaruM.TanasescuR.IliescuI.DumitrescuL.SilosiI. (2009). Expression of IL-6 activity in patients with acute ischemic stroke. Rom. J. Intern Med.47 (4), 393–396.

  • Google Scholar

• 47

  ColonnaM.ButovskyO. (2017). Microglia function in the central nervous system during health and neurodegeneration. Annu. Rev. Immunol.35, 441–468. 10.1146/annurev-immunol-051116-052358

  • CrossRef
  • Google Scholar

• 48

  ConradM.KaganV. E.BayirH.PagnussatG. C.HeadB.TraberM. G.et al (2018). Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev.32 (9-10), 602–619. 10.1101/gad.314674.118

  • CrossRef
  • Google Scholar

• 49

  CreganS. P.MaclaurinJ. G.CraigC. G.RobertsonG. S.NicholsonD. W.ParkD. S.et al (1999). Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J. Neurosci.19 (18), 7860–7869. 10.1523/jneurosci.19-18-07860.1999

  • CrossRef
  • Google Scholar

• 50

  CuiY.ZhangY.ZhaoX.ShaoL.LiuG.SunC.et al (2021). ACSL4 exacerbates ischemic stroke by promoting ferroptosis-induced brain injury and neuroinflammation. Brain Behav. Immun.93, 312–321. 10.1016/j.bbi.2021.01.003

  • CrossRef
  • Google Scholar

• 51

  CunnaneS. C. (1994). Antioxidants, free radicals and PUFA. Prostagl. Leukot. Essent. Fat. Acids50 (6), 363–364. 10.1016/0952-3278(94)90248-8

  • CrossRef
  • Google Scholar

• 52

  DanemanR.PratA. (2015). The blood-brain barrier. Cold Spring Harb. Perspect. Biol.7 (1), a020412. 10.1101/cshperspect.a020412

  • CrossRef
  • Google Scholar

• 53

  DasU. N. (2019). Saturated fatty acids, MUFAs and PUFAs regulate ferroptosis. Cell Chem. Biol.26 (3), 309–311. 10.1016/j.chembiol.2019.03.001

  • CrossRef
  • Google Scholar

• 54

  DavalosA.Fernandez-RealJ. M.RicartW.MolinsA.PlanasE.GenisD. (1994). Iron-related damage in acute ischemic stroke. Stroke25 (8), 1543–1546. 10.1161/01.str.25.8.1543

  • CrossRef
  • Google Scholar

• 55

  DavidoffM. S. (2019). The pluripotent microvascular pericytes are the adult stem cells even in the testis. Adv. Exp. Med. Biol.1122, 235–267. 10.1007/978-3-030-11093-2_13

  • CrossRef
  • Google Scholar

• 56

  Degregorio-RocasolanoN.Marti-SistacO.GasullT. (2019). Deciphering the iron side of stroke: Neurodegeneration at the crossroads between iron dyshomeostasis, excitotoxicity, and ferroptosis. Front. Neurosci.13, 85. 10.3389/fnins.2019.00085

  • CrossRef
  • Google Scholar

• 57

  Del ZoppoG. J. (1998). The role of platelets in ischemic stroke. Neurology51, S9–S14. 10.1212/wnl.51.3_suppl_3.s9

  • CrossRef
  • Google Scholar

• 58

  DewarD.UnderhillS. M.GoldbergM. P. (2003). Oligodendrocytes and ischemic brain injury. J. Cereb. Blood Flow. Metab.23 (3), 263–274. 10.1097/01.WCB.0000053472.41007.F9

  • CrossRef
  • Google Scholar

• 59

  DhakshinamoorthyS.LongD. J.2ndJaiswalA. K. (2000). Antioxidant regulation of genes encoding enzymes that detoxify xenobiotics and carcinogens. Curr. Top. Cell. Regul.36, 201–216. 10.1016/s0070-2137(01)80009-1

  • CrossRef
  • Google Scholar

• 60

  DixonS. J.LembergK. M.LamprechtM. R.SkoutaR.ZaitsevE. M.GleasonC. E.et al (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell149 (5), 1060–1072. 10.1016/j.cell.2012.03.042

  • CrossRef
  • Google Scholar

• 61

  Do VanB.GouelF.JonneauxA.TimmermanK.GeleP.PetraultM.et al (2016). Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC. Neurobiol. Dis.94, 169–178. 10.1016/j.nbd.2016.05.011

  • CrossRef
  • Google Scholar

• 62

  DollS.FreitasF. P.ShahR.AldrovandiM.da SilvaM. C.IngoldI.et al (2019). FSP1 is a glutathione-independent ferroptosis suppressor. Nature575 (7784), 693–698. 10.1038/s41586-019-1707-0

  • CrossRef
  • Google Scholar

• 63

  DollS.PronethB.TyurinaY. Y.PanziliusE.KobayashiS.IngoldI.et al (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol.13 (1), 91–98. 10.1038/nchembio.2239

  • CrossRef
  • Google Scholar

• 64

  DonkorE. S. (2018). Stroke in the 21(st) century: A snapshot of the burden, epidemiology, and quality of life. Stroke Res. Treat.2018, 3238165. 10.1155/2018/3238165

  • CrossRef
  • Google Scholar

• 65

  DugasJ. C.MandemakersW.RogersM.IbrahimA.DanemanR.BarresB. A. (2008). A novel purification method for CNS projection neurons leads to the identification of brain vascular cells as a source of trophic support for corticospinal motor neurons. J. Neurosci.28 (33), 8294–8305. 10.1523/JNEUROSCI.2010-08.2008

  • CrossRef
  • Google Scholar

• 66

  EarnshawW. C.MartinsL. M.KaufmannS. H. (1999). Mammalian caspases: Structure, activation, substrates, and functions during apoptosis. Annu. Rev. Biochem.68, 383–424. 10.1146/annurev.biochem.68.1.383

  • CrossRef
  • Google Scholar

• 67

  EnomotoM.EndoA.YatsushigeH.FushimiK.OtomoY. (2019). Clinical effects of early edaravone use in acute ischemic stroke patients treated by endovascular reperfusion therapy. Stroke50 (3), 652–658. 10.1161/STROKEAHA.118.023815

  • CrossRef
  • Google Scholar

• 68

  FangS.YuX.DingH.HanJ.FengJ. (2018). Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors. Biochem. Biophys. Res. Commun.503 (1), 297–303. 10.1016/j.bbrc.2018.06.019

  • CrossRef
  • Google Scholar

• 69

  FangX.WangH.HanD.XieE.YangX.WeiJ.et al (2019). Ferroptosis as a target for protection against cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A.116 (7), 2672–2680. 10.1073/pnas.1821022116

  • CrossRef
  • Google Scholar

• 70

  FederM. E.HofmannG. E. (1999). Heat-shock proteins, molecular chaperones, and the stress response: Evolutionary and ecological physiology. Annu. Rev. Physiol.61, 243–282. 10.1146/annurev.physiol.61.1.243

  • CrossRef
  • Google Scholar

• 71

  FeiW.ChenD.TangH.ZhengW.ChenF.ChenF.et al (2020). Targeted GSH-exhausting and hydroxyl radical self-producing manganese-silica nanomissiles for MRI guided ferroptotic cancer therapy. Nanoscale12 (32), 16738–16754. 10.1039/d0nr02396e

  • CrossRef
  • Google Scholar

• 72

  FengY.MadungweN. B.Imam AliaganA. D.TomboN.BopassaJ. C. (2019). Liproxstatin-1 protects the mouse myocardium against ischemia/reperfusion injury by decreasing VDAC1 levels and restoring GPX4 levels. Biochem. Biophys. Res. Commun.520 (3), 606–611. 10.1016/j.bbrc.2019.10.006

  • CrossRef
  • Google Scholar

• 73

  FergusonL. R.KarunasingheN.ZhuS.WangA. H. (2012). Selenium and its' role in the maintenance of genomic stability. Mutat. Res.733 (1-2), 100–110. 10.1016/j.mrfmmm.2011.12.011

  • CrossRef
  • Google Scholar

• 74

  Fernandez-MoralesJ. C.HuaW.YaoY.MoradM. (2019). Regulation of Ca(2+) signaling by acute hypoxia and acidosis in cardiomyocytes derived from human induced pluripotent stem cells. Cell Calcium78, 1–14. 10.1016/j.ceca.2018.12.006

  • CrossRef
  • Google Scholar

• 75

  ForcinaG. C.DixonS. J. (2019). GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics19 (18), e1800311. 10.1002/pmic.201800311

  • CrossRef
  • Google Scholar

• 76

  FriedmanM. (2014). Chemistry and multibeneficial bioactivities of carvacrol (4-isopropyl-2-methylphenol), a component of essential oils produced by aromatic plants and spices. J. Agric. Food Chem.62 (31), 7652–7670. 10.1021/jf5023862

  • CrossRef
  • Google Scholar

• 77

  FungF. Y.LinnY. C. (2015). Developing traditional Chinese medicine in the era of evidence-based medicine: Current evidences and challenges. Evid. Based. Complement. Altern. Med.2015, 425037. 10.1155/2015/425037

  • CrossRef
  • Google Scholar

• 78

  GaoM.MonianP.PanQ.ZhangW.XiangJ.JiangX. (2016). Ferroptosis is an autophagic cell death process. Cell Res.26 (9), 1021–1032. 10.1038/cr.2016.95

  • CrossRef
  • Google Scholar

• 79

  GaoM.YiJ.ZhuJ.MinikesA. M.MonianP.ThompsonC. B.et al (2019). Role of mitochondria in ferroptosis. Mol. Cell73 (2), 354–363. 10.1016/j.molcel.2018.10.042

  • CrossRef
  • Google Scholar

• 80

  GaschlerM. M.AndiaA. A.LiuH.CsukaJ. M.HurlockerB.VaianaC. A.et al (2018). FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat. Chem. Biol.14 (5), 507–515. 10.1038/s41589-018-0031-6

  • CrossRef
  • Google Scholar

• 81

  GaschlerM. M.StockwellB. R. (2017). Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun.482 (3), 419–425. 10.1016/j.bbrc.2016.10.086

  • CrossRef
  • Google Scholar

• 82

  GillessenT.BuddS. L.LiptonS. A. (2002). Excitatory amino acid neurotoxicity. Adv. Exp. Med. Biol.513, 3–40. 10.1007/978-1-4615-0123-7_1

  • CrossRef
  • Google Scholar

• 83

  GirottiA. W. (1998). Lipid hydroperoxide generation, turnover, and effector action in biological systems. J. Lipid Res.39 (8), 1529–1542. 10.1016/s0022-2275(20)32182-9

  • CrossRef
  • Google Scholar

• 84

  GriesmaierE.KellerM. (2012). Glutamate receptors - prenatal insults, long-term consequences. Pharmacol. Biochem. Behav.100 (4), 835–840. 10.1016/j.pbb.2011.04.011

  • CrossRef
  • Google Scholar

• 85

  GrignanoE.BirsenR.ChapuisN.BouscaryD. (2020). From iron chelation to overload as a therapeutic strategy to induce ferroptosis in leukemic cells. Front. Oncol.10, 586530. 10.3389/fonc.2020.586530

  • CrossRef
  • Google Scholar

• 86

  GuanT.SongJ.WangY.GuoL.YuanL.ZhaoY.et al (2017). Expression and characterization of recombinant bifunctional enzymes with glutathione peroxidase and superoxide dismutase activities. Free Radic. Biol. Med.110, 188–195. 10.1016/j.freeradbiomed.2017.06.005

  • CrossRef
  • Google Scholar

• 87

  GuanX.LiZ.ZhuS.ChengM.JuY.RenL.et al (2021). Galangin attenuated cerebral ischemia-reperfusion injury by inhibition of ferroptosis through activating the SLC7A11/GPX4 axis in gerbils. Life Sci.264, 118660. 10.1016/j.lfs.2020.118660

  • CrossRef
  • Google Scholar

• 88

  GuoS.KimW. J.LokJ.LeeS. R.BesanconE.LuoB. H.et al (2008). Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc. Natl. Acad. Sci. U. S. A.105 (21), 7582–7587. 10.1073/pnas.0801105105

  • CrossRef
  • Google Scholar

• 89

  GuoG. C.WangJ. X.HanM. L.ZhangL. P.LiL. (2017). microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression. Cell. Oncol.40 (2), 157–166. 10.1007/s13402-016-0312-6

  • CrossRef
  • Google Scholar

• 90

  HambrightW. S.FonsecaR. S.ChenL.NaR.RanQ. (2017). Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol.12, 8–17. 10.1016/j.redox.2017.01.021

  • CrossRef
  • Google Scholar

• 91

  HamelE. (2006). Perivascular nerves and the regulation of cerebrovascular tone. J. Appl. Physiol. (1985)100 (3), 1059–1064. 10.1152/japplphysiol.00954.2005

  • CrossRef
  • Google Scholar

• 92

  HamiltonN. B.AttwellD.HallC. N. (2010). Pericyte-mediated regulation of capillary diameter: A component of neurovascular coupling in health and disease. Front. Neuroenergetics2, 5. 10.3389/fnene.2010.00005

  • CrossRef
  • Google Scholar

• 93

  HansonL. R.RoeytenbergA.MartinezP. M.CoppesV. G.SweetD. C.RaoR. J.et al (2009). Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J. Pharmacol. Exp. Ther.330 (3), 679–686. 10.1124/jpet.108.149807

  • CrossRef
  • Google Scholar

• 94

  HarrisC. C. (1996). p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. Carcinogenesis17 (6), 1187–1198. 10.1093/carcin/17.6.1187

  • CrossRef
  • Google Scholar

• 95

  HarrisS. L.LevineA. J. (2005). The p53 pathway: Positive and negative feedback loops. Oncogene24 (17), 2899–2908. 10.1038/sj.onc.1208615

  • CrossRef
  • Google Scholar

• 96

  HenkeN.Schmidt-UllrichR.DechendR.ParkJ. K.QadriF.WellnerM.et al (2007). Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ. Res.101 (3), 268–276. 10.1161/CIRCRESAHA.107.150474

  • CrossRef
  • Google Scholar

• 97

  HongS. H.LeeD. H.LeeY. S.JoM. J.JeongY. A.KwonW. T.et al (2017). Molecular crosstalk between ferroptosis and apoptosis: Emerging role of ER stress-induced p53-independent PUMA expression. Oncotarget8 (70), 115164–115178. 10.18632/oncotarget.23046

  • CrossRef
  • Google Scholar

• 98

  HoriS.OhtsukiS.HosoyaK.NakashimaE.TerasakiT. (2004). A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J. Neurochem.89 (2), 503–513. 10.1111/j.1471-4159.2004.02343.x

  • CrossRef
  • Google Scholar

• 99

  HoshiO.UshikiT. (2004). Neutrophil extravasation in rat mesenteric venules induced by the chemotactic peptide N-formyl-methionyl-luecylphenylalanine (fMLP), with special attention to a barrier function of the vascular basal lamina for neutrophil migration. Arch. Histol. Cytol.67 (1), 107–114. 10.1679/aohc.67.107

  • CrossRef
  • Google Scholar

• 100

  HuH. J.SongM. (2017). Disrupted ionic homeostasis in ischemic stroke and new therapeutic targets. J. Stroke Cerebrovasc. Dis.26 (12), 2706–2719. 10.1016/j.jstrokecerebrovasdis.2017.09.011

  • CrossRef
  • Google Scholar

• 101

  HuX.De SilvaT. M.ChenJ.FaraciF. M. (2017). Cerebral vascular disease and neurovascular injury in ischemic stroke. Circ. Res.120 (3), 449–471. 10.1161/CIRCRESAHA.116.308427

  • CrossRef
  • Google Scholar

• 102

  HuX.WuD.HeX.ZhaoH.HeZ.LinJ.et al (2019). circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling. Mol. Cancer18 (1), 160. 10.1186/s12943-019-1095-y

  • CrossRef
  • Google Scholar

• 103

  HuangJ. (2021). Current developments of targeting the p53 signaling pathway for cancer treatment. Pharmacol. Ther.220, 107720. 10.1016/j.pharmthera.2020.107720

  • CrossRef
  • Google Scholar

• 104

  HughesS. M.LillienL. E.RaffM. C.RoHrerH.SendtnerM. (1988). Ciliary neurotrophic factor induces type-2 astrocyte differentiation in culture. Nature335 (6185), 70–73. 10.1038/335070a0

  • CrossRef
  • Google Scholar

• 105

  HundeshagenP.Hamacher-BradyA.EilsR.BradyN. R. (2011). Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy. BMC Biol.9, 38. 10.1186/1741-7007-9-38

  • CrossRef
  • Google Scholar

• 106

  HuoX.SunH.CaoD.YangJ.PengP.YuM.et al (2019). Identification of prognosis markers for endometrial cancer by integrated analysis of DNA methylation and RNA-Seq data. Sci. Rep.9 (1), 9924. 10.1038/s41598-019-46195-8

  • CrossRef
  • Google Scholar

• 107

  Hutter-SchmidB.HumpelC. (2016). Platelet-derived growth factor receptor-beta is differentially regulated in primary mouse pericytes and brain slices. Curr. Neurovasc. Res.13 (2), 127–134. 10.2174/1567202613666160219120411

  • CrossRef
  • Google Scholar

• 108

  IadecolaC. (2017). The neurovascular unit coming of age: A journey through neurovascular coupling in health and disease. Neuron96 (1), 17–42. 10.1016/j.neuron.2017.07.030

  • CrossRef
  • Google Scholar

• 109

  IkedaM.NakazawaT.AbeK.KanekoT.YamatsuK. (1989). Extracellular accumulation of glutamate in the hippocampus induced by ischemia is not calcium dependent--in vitro and in vivo evidence. Neurosci. Lett.96 (2), 202–206. 10.1016/0304-3940(89)90058-x

  • CrossRef
  • Google Scholar

• 110

  Ikeshima-KataokaH. (2016). Neuroimmunological implications of AQP4 in astrocytes. Int. J. Mol. Sci.17 (8), E1306. 10.3390/ijms17081306

  • CrossRef
  • Google Scholar

• 111

  IllesP.VerkhratskyA.TangY. (2021). Surveilling microglia dampens neuronal activity: Operation of a purinergically mediated negative feedback mechanism. Signal Transduct. Target. Ther.6 (1), 160. 10.1038/s41392-021-00586-4

  • CrossRef
  • Google Scholar

• 112

  IshikawaM.ZhangJ. H.NandaA.GrangerD. N. (2004). Inflammatory responses to ischemia and reperfusion in the cerebral microcirculation. Front. Biosci.9, 1339–1347. 10.2741/1330

  • CrossRef
  • Google Scholar

• 113

  JacobsA.MillerF.WorwoodM.WardropC. A. (1972). Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. Br. Med. J.4 (5834), 206–208. 10.1136/bmj.4.5834.206

  • CrossRef
  • Google Scholar

• 114

  JaenischR.BirdA. (2003). Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat. Genet.33, 245–254. 10.1038/ng1089

  • CrossRef
  • Google Scholar

• 115

  JaiswalA. K. (2004). Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med.36 (10), 1199–1207. 10.1016/j.freeradbiomed.2004.02.074

  • CrossRef
  • Google Scholar

• 116

  JiH.WangW.LiX.HanX.ZhangX.WangJ.et al (2022). p53: A double-edged sword in tumor ferroptosis. Pharmacol. Res.177, 106013. 10.1016/j.phrs.2021.106013

  • CrossRef
  • Google Scholar

• 117

  JiangL.KonN.LiT.WangS. J.SuT.HibshooshH.et al (2015). Ferroptosis as a p53-mediated activity during tumour suppression. Nature520 (7545), 57–62. 10.1038/nature14344

  • CrossRef
  • Google Scholar

• 118

  JiangX.StockwellB. R.ConradM. (2021). Ferroptosis: Mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol.22 (4), 266–282. 10.1038/s41580-020-00324-8

  • CrossRef
  • Google Scholar

• 119

  JinG.AraiK.MurataY.WangS.StinsM. F.LoE. H.et al (2008). Protecting against cerebrovascular injury: Contributions of 12/15-lipoxygenase to edema formation after transient focal ischemia. Stroke39 (9), 2538–2543. 10.1161/STROKEAHA.108.514927

  • CrossRef
  • Google Scholar

• 120

  JonesG.GoswamiS. K.KangH.ChoiH. S.KimJ. (2020). Combating iron overload: A case for deferoxamine-based nanochelators. Nanomedicine (Lond)15, 1341–1356. 10.2217/nnm-2020-0038

  • CrossRef
  • Google Scholar

• 121

  KaganV. E.MaoG.QuF.AngeliJ. P. F.DollS.CroixC. S.et al (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol.13 (1), 81–90. 10.1038/nchembio.2238

  • CrossRef
  • Google Scholar

• 122

  KakhlonO.CabantchikZ. I. (2002). The labile iron pool: Characterization, measurement, and participation in cellular processes(1). Free Radic. Biol. Med.33 (8), 1037–1046. 10.1016/s0891-5849(02)01006-7

  • CrossRef
  • Google Scholar

• 123

  KangR.GamdzykM.LenahanC.TangJ.TanS.ZhangJ. H. (2020). The dual role of microglia in blood-brain barrier dysfunction after stroke. Curr. Neuropharmacol.18 (12), 1237–1249. 10.2174/1570159X18666200529150907

  • CrossRef
  • Google Scholar

• 124

  KannerJ.GermanJ. B.KinsellaJ. E. (1987). Initiation of lipid peroxidation in biological systems. Crit. Rev. Food Sci. Nutr.25 (4), 317–364. 10.1080/10408398709527457

  • CrossRef
  • Google Scholar

• 125

  KasparJ. W.NitureS. K.JaiswalA. K. (2009). Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med.47 (9), 1304–1309. 10.1016/j.freeradbiomed.2009.07.035

  • CrossRef
  • Google Scholar

• 126

  KawabataH. (2019). Transferrin and transferrin receptors update. Free Radic. Biol. Med.133, 46–54. 10.1016/j.freeradbiomed.2018.06.037

  • CrossRef
  • Google Scholar

• 127

  KernF.StanikaR. I.SargB.OffterdingerM.HessD.ObermairG. J.et al (2013). Nogo-A couples with Apg-1 through interaction and co-ordinate expression under hypoxic and oxidative stress. Biochem. J.455 (2), 217–227. 10.1042/BJ20130579

  • CrossRef
  • Google Scholar

• 128

  KhoshnamS. E.WinlowW.FarzanehM.FarboodY.MoghaddamH. F. (2017). Pathogenic mechanisms following ischemic stroke. Neurol. Sci.38 (7), 1167–1186. 10.1007/s10072-017-2938-1

  • CrossRef
  • Google Scholar

• 129

  KikuchiK.TancharoenS.MatsudaF.BiswasK. K.ItoT.MorimotoY.et al (2009). Edaravone attenuates cerebral ischemic injury by suppressing aquaporin-4. Biochem. Biophys. Res. Commun.390 (4), 1121–1125. 10.1016/j.bbrc.2009.09.015

  • CrossRef
  • Google Scholar

• 130

  KikuchiK.TancharoenS.TakeshigeN.YoshitomiM.MoriokaM.MuraiY.et al (2013). The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int. J. Mol. Sci.14 (7), 13909–13930. 10.3390/ijms140713909

  • CrossRef
  • Google Scholar

• 131

  KimS. E.ZhangL.MaK.RiegmanM.ChenF.IngoldI.et al (2016). Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth. Nat. Nanotechnol.11 (11), 977–985. 10.1038/nnano.2016.164

  • CrossRef
  • Google Scholar

• 132

  KimS. U.De VellisJ. (2005). Microglia in health and disease. J. Neurosci. Res.81 (3), 302–313. 10.1002/jnr.20562

  • CrossRef
  • Google Scholar

• 133

  KobayashiM.YamamotoM. (2006). Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul.46, 113–140. 10.1016/j.advenzreg.2006.01.007

  • CrossRef
  • Google Scholar

• 134

  KobayashiS.FukumaS.IkenoueT.FukuharaS. (2019). Effect of edaravone on neurological symptoms in real-world patients with acute ischemic stroke. Stroke50 (7), 1805–1811. 10.1161/STROKEAHA.118.024351

  • CrossRef
  • Google Scholar

• 135

  KohP. O. (2008). Melatonin attenuates the focal cerebral ischemic injury by inhibiting the dissociation of pBad from 14-3-3. J. Pineal Res.44 (1), 101–106. 10.1111/j.1600-079X.2007.00495.x

  • CrossRef
  • Google Scholar

• 136

  Kruger-GengeA.BlockiA.FrankeR. P.JungF. (2019). Vascular endothelial cell biology: An update. Int. J. Mol. Sci.20 (18), E4411. 10.3390/ijms20184411

  • CrossRef
  • Google Scholar

• 137

  KuangF.LiuJ.TangD.KangR. (2020). Oxidative damage and antioxidant defense in ferroptosis. Front. Cell Dev. Biol.8, 586578. 10.3389/fcell.2020.586578

  • CrossRef
  • Google Scholar

• 138

  KuhnS.GrittiL.CrooksD.DombrowskiY. (2019). Oligodendrocytes in development, myelin generation and beyond. Cells8 (11), E1424. 10.3390/cells8111424

  • CrossRef
  • Google Scholar

• 139

  KuwataH.NakataniE.Shimbara-MatsubayashiS.IshikawaF.ShibanumaM.SasakiY.et al (2019). Long-chain acyl-CoA synthetase 4 participates in the formation of highly unsaturated fatty acid-containing phospholipids in murine macrophages. Biochim. Biophys. Acta. Mol. Cell Biol. Lipids1864 (11), 1606–1618. 10.1016/j.bbalip.2019.07.013

  • CrossRef
  • Google Scholar

• 140

  KwakM. K.ChoJ. M.HuangB.ShinS.KenslerT. W. (2007). Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. Free Radic. Biol. Med.43 (5), 809–817. 10.1016/j.freeradbiomed.2007.05.029

  • CrossRef
  • Google Scholar

• 141

  LaiT. W.ZhangS.WangY. T. (2014). Excitotoxicity and stroke: Identifying novel targets for neuroprotection. Prog. Neurobiol.115, 157–188. 10.1016/j.pneurobio.2013.11.006

  • CrossRef
  • Google Scholar

• 142

  LanB.GeJ. W.ChengS. W.ZhengX. L.LiaoJ.HeC.et al (2020). Extract of Naotaifang, a compound Chinese herbal medicine, protects neuron ferroptosis induced by acute cerebral ischemia in rats. J. Integr. Med.18 (4), 344–350. 10.1016/j.joim.2020.01.008

  • CrossRef
  • Google Scholar

• 143

  LaneD. J. R.AytonS.BushA. I. (2018). Iron and alzheimer's disease: An update on emerging mechanisms. J. Alzheimers Dis.64, S379–S395. 10.3233/JAD-179944

  • CrossRef
  • Google Scholar

• 144

  LaoY.WangY.ChenJ.HuangP.SuR.ShiJ.et al (2022). Synthesis and biological evaluation of 1, 2, 4-triazole derivatives as potential Nrf2 activators for the treatment of cerebral ischemic injury. Eur. J. Med. Chem.236, 114315. 10.1016/j.ejmech.2022.114315

  • CrossRef
  • Google Scholar

• 145

  LazarovO.HollandsC. (2016). Hippocampal neurogenesis: Learning to remember. Prog. Neurobiol.138-140, 1–18. 10.1016/j.pneurobio.2015.12.006

  • CrossRef
  • Google Scholar

• 146

  LeeJ. Y.KimW. K.BaeK. H.LeeS. C.LeeE. W. (2021). Lipid metabolism and ferroptosis. Biol. (Basel)10 (3), 184. 10.3390/biology10030184

  • CrossRef
  • Google Scholar

• 147

  LeighR.KnutssonL.ZhouJ.van ZijlP. C. (2018). Imaging the physiological evolution of the ischemic penumbra in acute ischemic stroke. J. Cereb. Blood Flow. Metab.38 (9), 1500–1516. 10.1177/0271678X17700913

  • CrossRef
  • Google Scholar

• 148

  LemastersJ. J. (2017). Evolution of voltage-dependent anion channel function: From molecular sieve to governator to actuator of ferroptosis. Front. Oncol.7, 303. 10.3389/fonc.2017.00303

  • CrossRef
  • Google Scholar

• 149

  LiZ.HuaC.PanX.FuX.WuW. (2016). Carvacrol exerts neuroprotective effects via suppression of the inflammatory response in middle cerebral artery occlusion rats. Inflammation39 (4), 1566–1572. 10.1007/s10753-016-0392-5

  • CrossRef
  • Google Scholar

• 150

  LiY.FengD.WangZ.ZhaoY.SunR.TianD.et al (2019). Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ.26 (11), 2284–2299. 10.1038/s41418-019-0299-4

  • CrossRef
  • Google Scholar

• 151

  LiX.MaN.XuJ.ZhangY.YangP.SuX.et al (2021). Targeting ferroptosis: Pathological mechanism and treatment of ischemia-reperfusion injury. Oxid. Med. Cell. Longev.2021, 1587922. 10.1155/2021/1587922

  • CrossRef
  • Google Scholar

• 152

  LimS.KimT. J.KimY. J.KimC.KoS. B.KimB. S. (2021). Senolytic therapy for cerebral ischemia-reperfusion injury. Int. J. Mol. Sci.22 (21), 11967. 10.3390/ijms222111967

  • CrossRef
  • Google Scholar

• 153

  LittarruG. P.TianoL. (2007). Bioenergetic and antioxidant properties of coenzyme Q10: Recent developments. Mol. Biotechnol.37 (1), 31–37. 10.1007/s12033-007-0052-y

  • CrossRef
  • Google Scholar

• 154

  LiuL.VollmerM. K.FernandezV. M.DweikY.KimH.DoreS. (2018). Korean red ginseng pretreatment protects against long-term sensorimotor deficits after ischemic stroke likely through Nrf2. Front. Cell. Neurosci.12, 74. 10.3389/fncel.2018.00074

  • CrossRef
  • Google Scholar

• 155

  LiuJ.ZhangC.WangJ.HuW.FengZ. (2020). The regulation of ferroptosis by tumor suppressor p53 and its pathway. Int. J. Mol. Sci.21 (21), E8387. 10.3390/ijms21218387

  • CrossRef
  • Google Scholar

• 156

  LiuJ.GuoZ. N.YanX. L.HuangS.RenJ. X.LuoY.et al (2020). Crosstalk between autophagy and ferroptosis and its putative role in ischemic stroke. Front. Cell. Neurosci.14, 577403. 10.3389/fncel.2020.577403

  • CrossRef
  • Google Scholar

• 157

  LiuL.WangM.GongN.TianP.DengH. (2021). Se improves GPX4 expression and SOD activity to alleviate heat-stress-induced ferroptosis-like death in goat mammary epithelial cells. Anim. Cells Syst.25 (5), 283–295. 10.1080/19768354.2021.1988704

  • CrossRef
  • Google Scholar

• 158

  LoE. H.RosenbergG. A. (2009). The neurovascular unit in health and disease: Introduction. Stroke40 (3), S2–S3. 10.1161/STROKEAHA.108.534404

  • CrossRef
  • Google Scholar

• 159

  Lopes-BezerraL. M.FillerS. G. (2003). Endothelial cells, tissue factor and infectious diseases. Braz J. Med. Biol. Res.36 (8), 987–991. 10.1590/s0100-879x2003000800004

  • CrossRef
  • Google Scholar

• 160

  Lopes-MarquesM.CunhaI.Reis-HenriquesM. A.SantosM. M.CastroL. F. C. (2013). Diversity and history of the long-chain acyl-CoA synthetase (Acsl) gene family in vertebrates. BMC Evol. Biol.13, 271. 10.1186/1471-2148-13-271

  • CrossRef
  • Google Scholar

• 161

  LuB.ChenX. B.YingM. D.HeQ. J.CaoJ.YangB. (2017). The role of ferroptosis in cancer development and treatment response. Front. Pharmacol.8, 992. 10.3389/fphar.2017.00992

  • CrossRef
  • Google Scholar

• 162

  LuoM.WuL.ZhangK.WangH.ZhangT.GutierrezL.et al (2018). miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death Differ.25 (8), 1457–1472. 10.1038/s41418-017-0053-8

  • CrossRef
  • Google Scholar

• 163

  LuoW.WangJ.DaiX.ZhangH.QuY.XiaoW.et al (2021). ACSL4 expression is associated with CD8+ T cell infiltration and immune response in bladder cancer. Front. Oncol.11, 754845. 10.3389/fonc.2021.754845

  • CrossRef
  • Google Scholar

• 164

  MaY.ZhangX.AlsaidanO. A.YangX.SulejmaniE.ZhaJ.et al (2021). Long-chain acyl-CoA synthetase 4-mediated fatty acid metabolism sustains androgen receptor pathway-independent prostate cancer. Mol. Cancer Res.19 (1), 124–135. 10.1158/1541-7786.MCR-20-0379

  • CrossRef
  • Google Scholar

• 165

  MagtanongL.DixonS. J. (2018). Ferroptosis and brain injury. Dev. Neurosci.40 (5-6), 382–395. 10.1159/000496922

  • CrossRef
  • Google Scholar

• 166

  MagtanongL.KoP. J.DixonS. J. (2016). Emerging roles for lipids in non-apoptotic cell death. Cell Death Differ.23 (7), 1099–1109. 10.1038/cdd.2016.25

  • CrossRef
  • Google Scholar

• 167

  Mahoney-SanchezL.BouchaouiH.AytonS.DevosD.DuceJ. A.DevedjianJ. C. (2021). Ferroptosis and its potential role in the physiopathology of Parkinson's Disease. Prog. Neurobiol.196, 101890. 10.1016/j.pneurobio.2020.101890

  • CrossRef
  • Google Scholar

• 168

  MakiharaN.ArimuraK.AgoT.TachibanaM.NishimuraA.NakamuraK.et al (2015). Involvement of platelet-derived growth factor receptor beta in fibrosis through extracellular matrix protein production after ischemic stroke. Exp. Neurol.264, 127–134. 10.1016/j.expneurol.2014.12.007

  • CrossRef
  • Google Scholar

• 169

  ManciasJ. D.WangX.GygiS. P.HarperJ. W.KimmelmanA. C. (2014). Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature509 (7498), 105–109. 10.1038/nature13148

  • CrossRef
  • Google Scholar

• 170

  MandaiK.MatsumotoM.KitagawaK.MatsushitaK.OhTsukiT.MabuchiT.et al (1997). Ischemic damage and subsequent proliferation of oligodendrocytes in focal cerebral ischemia. Neuroscience77 (3), 849–861. 10.1016/s0306-4522(96)00517-9

  • CrossRef
  • Google Scholar

• 171

  MarceloK. L.GoldieL. C.HirschiK. K. (2013). Regulation of endothelial cell differentiation and specification. Circ. Res.112 (9), 1272–1287. 10.1161/CIRCRESAHA.113.300506

  • CrossRef
  • Google Scholar

• 172

  MargisR.DunandC.TeixeiraF. K.Margis-PinheiroM. (2008). Glutathione peroxidase family - an evolutionary overview. FEBS J.275 (15), 3959–3970. 10.1111/j.1742-4658.2008.06542.x

  • CrossRef
  • Google Scholar

• 173

  MartinA.DomercqM.MatuteC. (2018). Inflammation in stroke: The role of cholinergic, purinergic and glutamatergic signaling. Ther. Adv. Neurol. Disord.11, 1756286418774267. 10.1177/1756286418774267

  • CrossRef
  • Google Scholar

• 174

  MatsumotoJ.DohguS.TakataF.MachidaT.Bolukbasi HatipF. F.Hatip-Al-KhatibI.et al (2018). TNF-α-sensitive brain pericytes activate microglia by releasing IL-6 through cooperation between IκB-NFκB and JAK-STAT3 pathways. Brain Res.1692, 34–44. 10.1016/j.brainres.2018.04.023

  • CrossRef
  • Google Scholar

• 175

  MatsumotoS.MurozonoM.KanazawaM.NaraT.OzawaT.WatanabeY. (2018). Edaravone and cyclosporine A as neuroprotective agents for acute ischemic stroke. Acute Med. Surg.5 (3), 213–221. 10.1002/ams2.343

  • CrossRef
  • Google Scholar

• 176

  MatuteC.DomercqM.Sanchez-GomezM. V. (2006). Glutamate-mediated glial injury: Mechanisms and clinical importance. Glia53 (2), 212–224. 10.1002/glia.20275

  • CrossRef
  • Google Scholar

• 177

  MccallJ. M.BraughlerJ. M.HallE. D. (1987). Lipid peroxidation and the role of oxygen radicals in CNS injury. Acta Anaesthesiol. belg.38 (4), 373–379.

  • Google Scholar

• 178

  McconnellH. L.KerschC. N.WoltjerR. L.NeuweltE. A. (2017). The translational significance of the neurovascular unit. J. Biol. Chem.292 (3), 762–770. 10.1074/jbc.R116.760215

  • CrossRef
  • Google Scholar

• 179

  NarayanS. K.Grace CherianS.Babu PhanitiP.Babu ChidambaramS.Rachel VasanthiA. H.ArumugamM. (2021). Preclinical animal studies in ischemic stroke: Challenges and some solutions. Anim. Model. Exp. Med.4 (2), 104–115. 10.1002/ame2.12166

  • CrossRef
  • Google Scholar

• 180

  NasoohiS.SimaniL.KhodagholiF.NiksereshtS.FaiziM.NaderiN. (2019). Coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin. Nutr. Neurosci.22 (4), 264–272. 10.1080/1028415X.2017.1376928

  • CrossRef
  • Google Scholar

• 181

  NaveK. A.WernerH. B. (2014). Myelination of the nervous system: Mechanisms and functions. Annu. Rev. Cell Dev. Biol.30, 503–533. 10.1146/annurev-cellbio-100913-013101

  • CrossRef
  • Google Scholar

• 182

  Newell-PriceJ.ClarkA. J.KingP. (2000). DNA methylation and silencing of gene expression. Trends Endocrinol. Metab.11 (4), 142–148. 10.1016/s1043-2760(00)00248-4

  • CrossRef
  • Google Scholar

• 183

  NgS. W.NorwitzS. G.NorwitzE. R. (2019). The impact of iron overload and ferroptosis on reproductive disorders in humans: Implications for preeclampsia. Int. J. Mol. Sci.20 (13), E3283. 10.3390/ijms20133283

  • CrossRef
  • Google Scholar

• 184

  NguyenB.BixG.YaoY. (2021). Basal lamina changes in neurodegenerative disorders. Mol. Neurodegener.16 (1), 81. 10.1186/s13024-021-00502-y

  • CrossRef
  • Google Scholar

• 185

  NimmerjahnA.KirchhoffF.HelmchenF. (2005). Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science308 (5726), 1314–1318. 10.1126/science.1110647

  • CrossRef
  • Google Scholar

• 186

  NishizawaH.MatsumotoM.ChenG.IshiiY.TadaK.OnoderaM.et al (2021). Lipid peroxidation and the subsequent cell death transmitting from ferroptotic cells to neighboring cells. Cell Death Dis.12 (4), 332. 10.1038/s41419-021-03613-y

  • CrossRef
  • Google Scholar

• 187

  OnatD.BrillonD.ColomboP. C.SchmidtA. M. (2011). Human vascular endothelial cells: A model system for studying vascular inflammation in diabetes and atherosclerosis. Curr. Diab. Rep.11 (3), 193–202. 10.1007/s11892-011-0182-2

  • CrossRef
  • Google Scholar

• 188

  OwolabiM. O.Akarolo-AnthonyS.AkinyemiR.ArnettD.GebregziabherM.JenkinsC.et al (2015). The burden of stroke in africa: A glance at the present and a glimpse into the future. Cardiovasc. J. Afr.26, S27–S38. 10.5830/CVJA-2015-038

  • CrossRef
  • Google Scholar

• 189

  PanL.ZhouL.YinW.BaiJ.LiuR. (2018). miR-125a induces apoptosis, metabolism disorder and migrationimpairment in pancreatic cancer cells by targeting Mfn2-related mitochondrial fission. Int. J. Oncol.53 (1), 124–136. 10.3892/ijo.2018.4380

  • CrossRef
  • Google Scholar

• 190

  PapanicolaouK. N.KhairallahR. J.NgohG. A.ChikandoA.LuptakI.O'SheaK. M.et al (2011). Mitofusin-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes. Mol. Cell. Biol.31 (6), 1309–1328. 10.1128/MCB.00911-10

  • CrossRef
  • Google Scholar

• 191

  PardridgeW. M. (1991). Advances in cell biology of blood-brain barrier transport. Semin. Cell Biol.2 (6), 419–426.

  • Google Scholar

• 192

  PeiskerT.KoznarB.StetkarovaI.WidimskyP. (2017). Acute stroke therapy: A review. Trends cardiovasc. Med.27 (1), 59–66. 10.1016/j.tcm.2016.06.009

  • CrossRef
  • Google Scholar

• 193

  PengL.ZhaoY.LiY.ZhouY.LiL.LeiS.et al (2019). Effect of DJ-1 on the neuroprotection of astrocytes subjected to cerebral ischemia/reperfusion injury. J. Mol. Med.97 (2), 189–199. 10.1007/s00109-018-1719-5

  • CrossRef
  • Google Scholar

• 194

  PetrovaJ.ManolovV.VasilevV.TzatchevK.MarinovB. (2016). Ischemic stroke, inflammation, iron overload - connection to a hepcidin. Int. J. Stroke11 (1), NP16–17. 10.1177/1747493015607509

  • CrossRef
  • Google Scholar

• 195

  PlemelJ. R.KeoughM. B.DuncanG. J.SparlingJ. S.YongV. W.StysP. K.et al (2014). Remyelination after spinal cord injury: Is it a target for repair?Prog. Neurobiol.117, 54–72. 10.1016/j.pneurobio.2014.02.006

  • CrossRef
  • Google Scholar

• 196

  PolewskiM. D.Reveron-ThorntonR. F.CherryholmesG. A.MarinovG. K.CassadyK.AboodyK. S. (2016). Increased expression of system xc- in glioblastoma confers an altered metabolic state and temozolomide resistance. Mol. Cancer Res.14 (12), 1229–1242. 10.1158/1541-7786.MCR-16-0028

  • CrossRef
  • Google Scholar

• 197

  PrattD. A.TallmanK. A.PorterN. A. (2011). Free radical oxidation of polyunsaturated lipids: New mechanistic insights and the development of peroxyl radical clocks. Acc. Chem. Res.44 (6), 458–467. 10.1021/ar200024c

  • CrossRef
  • Google Scholar

• 198

  PurohitP. K.EdwardsR.TokatlidisK.SainiN. (2019). MiR-195 regulates mitochondrial function by targeting mitofusin-2 in breast cancer cells. RNA Biol.16 (7), 918–929. 10.1080/15476286.2019.1600999

  • CrossRef
  • Google Scholar

• 199

  QinD. J.TangC. X.YangL.LeiH.WeiW.WangY. Y.et al (2015). Hsp90 is a novel target molecule of CDDO-me in inhibiting proliferation of ovarian cancer cells. PLoS One10 (7), e0132337. 10.1371/journal.pone.0132337

  • CrossRef
  • Google Scholar

• 200

  QinC.ZhouL. Q.MaX. T.HuZ. W.YangS.ChenM.et al (2019). Dual functions of microglia in ischemic stroke. Neurosci. Bull.35 (5), 921–933. 10.1007/s12264-019-00388-3

  • CrossRef
  • Google Scholar

• 201

  RajS.KhuranaS.ChoudhariR.KesariK. K.KamalM. A.GargN.et al (2021). Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy. Semin. Cancer Biol.69, 166–177. 10.1016/j.semcancer.2019.11.002

  • CrossRef
  • Google Scholar

• 202

  RamakrishnanS.AnandV.RoyS. (2014). Vascular endothelial growth factor signaling in hypoxia and inflammation. J. Neuroimmune Pharmacol.9 (2), 142–160. 10.1007/s11481-014-9531-7

  • CrossRef
  • Google Scholar

• 203

  RamezaniM.SimaniL.AbediS.PakdamanH. (2021). Is selenium supplementation beneficial in acute ischemic stroke?Neurologist27 (2), 51–55. 10.1097/NRL.0000000000000365

  • CrossRef
  • Google Scholar

• 204

  RavingerovaT.KindernayL.BartekovaM.FerkoM.AdameovaA.ZohdiV.et al (2020). The molecular mechanisms of iron metabolism and its role in cardiac dysfunction and cardioprotection. Int. J. Mol. Sci.21 (21), E7889. 10.3390/ijms21217889

  • CrossRef
  • Google Scholar

• 205

  ReichertC. O.De FreitasF. A.Sampaio-SilvaJ.Rokita-RosaL.BarrosP. d. L.LevyD.et al (2020). Ferroptosis mechanisms involved in neurodegenerative diseases. Int. J. Mol. Sci.21 (22), E8765. 10.3390/ijms21228765

  • CrossRef
  • Google Scholar

• 206

  RenX.HuH.FarooqiI.SimpkinsJ. W. (2020). Blood substitution therapy rescues the brain of mice from ischemic damage. Nat. Commun.11 (1), 4078. 10.1038/s41467-020-17930-x

  • CrossRef
  • Google Scholar

• 207

  RinglebP. A.SchellingerP. D.SchranzC.HackeW. (2002). Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: Useful or harmful?Stroke33 (5), 1437–1441. 10.1161/01.str.0000015555.21285.db

  • CrossRef
  • Google Scholar

• 208

  RizzardiN.LiparuloI.AntonelliG.OrsiniF.RivaA.BergaminiC.et al (2021). Coenzyme Q10 phytosome formulation improves CoQ10 bioavailability and mitochondrial functionality in cultured cells. Antioxidants10 (6), 927. 10.3390/antiox10060927

  • CrossRef
  • Google Scholar

• 209

  RoemhildK.Von MaltzahnF.WeiskirchenR.KnuchelR.von StillfriedS.LammersT. (2021). Iron metabolism: Pathophysiology and pharmacology. Trends Pharmacol. Sci.42 (8), 640–656. 10.1016/j.tips.2021.05.001

  • CrossRef
  • Google Scholar

• 210

  RohnertP.SchroderU. H.ZiabrevaI.TagerM.ReymannK. G.StriggowF. (2012). Insufficient endogenous redox buffer capacity may underlie neuronal vulnerability to cerebral ischemia and reperfusion. J. Neurosci. Res.90 (1), 193–202. 10.1002/jnr.22754

  • CrossRef
  • Google Scholar

• 211

  RotinD.RobinsonB.TannockI. F. (1986). Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: Potential implications for cell death in tumors. Cancer Res.46 (6), 2821–2826.

  • Google Scholar

• 212

  RustenhovenJ.JanssonD.SmythL. C.DragunowM. (2017). Brain pericytes as mediators of neuroinflammation. Trends Pharmacol. Sci.38 (3), 291–304. 10.1016/j.tips.2016.12.001

  • CrossRef
  • Google Scholar

• 213

  SaccoR. L.KasnerS. E.BroderickJ. P.CaplanL. R.ConnorsJ. J. B.CulebrasA.et al (2013). An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American heart association/American stroke association. Stroke44 (7), 2064–2089. 10.1161/STR.0b013e318296aeca

  • CrossRef
  • Google Scholar

• 214

  SandooA.Van ZantenJ. J.MetsiosG. S.CarrollD.KitasG. D. (2010). The endothelium and its role in regulating vascular tone. Open cardiovasc. Med. J.4, 302–312. 10.2174/1874192401004010302

  • CrossRef
  • Google Scholar

• 215

  SasakiH.SatoH.Kuriyama-MatsumuraK.MaebaraK.WangH.TambaM.et al (2002). Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem.277 (47), 44765–44771. 10.1074/jbc.M208704200

  • CrossRef
  • Google Scholar

• 216

  SatoH.TambaM.IshiiT.BannaiS. (1999). Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem.274 (17), 11455–11458. 10.1074/jbc.274.17.11455

  • CrossRef
  • Google Scholar

• 217

  SchellingerP. D.WarachS. (2004). Therapeutic time window of thrombolytic therapy following stroke. Curr. Atheroscler. Rep.6 (4), 288–294. 10.1007/s11883-004-0060-3

  • CrossRef
  • Google Scholar

• 218

  SeibT. M.PatelS. A.BridgesR. J. (2011). Regulation of the system x(C)- cystine/glutamate exchanger by intracellular glutathione levels in rat astrocyte primary cultures. Glia59 (10), 1387–1401. 10.1002/glia.21176

  • CrossRef
  • Google Scholar

• 219

  ShenZ.XiangM.ChenC.DingF.WangY.ShangC.et al (2022). Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke. Biomed. Pharmacother.151, 113125. 10.1016/j.biopha.2022.113125

  • CrossRef
  • Google Scholar

• 220

  ShibataY.YasuiH.HigashikawaK.MiyamotoN.KugeY. (2019). Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo. PLoS One14 (12), e0225931. 10.1371/journal.pone.0225931

  • CrossRef
  • Google Scholar

• 221

  ShibuyaM. (2011). Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. Genes Cancer2 (12), 1097–1105. 10.1177/1947601911423031

  • CrossRef
  • Google Scholar

• 222

  ShihA. Y.LiP.MurphyT. H. (2005). A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J. Neurosci.25 (44), 10321–10335. 10.1523/JNEUROSCI.4014-05.2005

  • CrossRef
  • Google Scholar

• 223

  ShintokuR.TakigawaY.YamadaK.KubotaC.YoshimotoY.TakeuchiT.et al (2017). Lipoxygenase-mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3. Cancer Sci.108 (11), 2187–2194. 10.1111/cas.13380

  • CrossRef
  • Google Scholar

• 224

  SinghN. K.RaoG. N. (2019). Emerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies. Prog. Lipid Res.73, 28–45. 10.1016/j.plipres.2018.11.001

  • CrossRef
  • Google Scholar

• 225

  SoehnleinO.LindbomL. (2010). Phagocyte partnership during the onset and resolution of inflammation. Nat. Rev. Immunol.10 (6), 427–439. 10.1038/nri2779

  • CrossRef
  • Google Scholar

• 226

  SofroniewM. V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci.32 (12), 638–647. 10.1016/j.tins.2009.08.002

  • CrossRef
  • Google Scholar

• 227

  SongX.LongD. (2020). Nrf2 and ferroptosis: A new research direction for neurodegenerative diseases. Front. Neurosci.14, 267. 10.3389/fnins.2020.00267

  • CrossRef
  • Google Scholar

• 228

  StamatovicS. M.KeepR. F.AndjelkovicA. V. (2008). Brain endothelial cell-cell junctions: How to "open" the blood brain barrier. Curr. Neuropharmacol.6 (3), 179–192. 10.2174/157015908785777210

  • CrossRef
  • Google Scholar

• 229

  StanimirovicD. B.FriedmanA. (2012). Pathophysiology of the neurovascular unit: Disease cause or consequence?J. Cereb. Blood Flow. Metab.32 (7), 1207–1221. 10.1038/jcbfm.2012.25

  • CrossRef
  • Google Scholar

• 230

  SteinbergS. F. (2008). Structural basis of protein kinase C isoform function. Physiol. Rev.88 (4), 1341–1378. 10.1152/physrev.00034.2007

  • CrossRef
  • Google Scholar

• 231

  StockwellB. R.Friedmann AngeliJ. P.BayirH.BushA. I.ConradM.DixonS. J.et al (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell171 (2), 273–285. 10.1016/j.cell.2017.09.021

  • CrossRef
  • Google Scholar

• 232

  StubbsC. D.SmithA. D. (1984). The modification of mammalian membrane polyunsaturated fatty acid composition in relation to membrane fluidity and function. Biochim. Biophys. Acta779 (1), 89–137. 10.1016/0304-4157(84)90005-4

  • CrossRef
  • Google Scholar

• 233

  SuL. J.ZhangJ. H.GomezH.MuruganR.HongX.XuD.et al (2019). Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid. Med. Cell. Longev.2019, 5080843. 10.1155/2019/5080843

  • CrossRef
  • Google Scholar

• 234

  SukiennickiG. M.MarciniakW.MuszynskaM.BaszukP.GuptaS.BialkowskaK.et al (2019). Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence. PLoS One14 (1), e0208610. 10.1371/journal.pone.0208610

  • CrossRef
  • Google Scholar

• 235

  SunX.OuZ.XieM.KangR.FanY.NiuX.et al (2015). HSPB1 as a novel regulator of ferroptotic cancer cell death. Oncogene34 (45), 5617–5625. 10.1038/onc.2015.32

  • CrossRef
  • Google Scholar

• 236

  TangL. J.ZhouY. J.XiongX. M.LiN. S.ZhangJ. J.LuoX. J.et al (2021). Ubiquitin-specific protease 7 promotes ferroptosis via activation of the p53/TfR1 pathway in the rat hearts after ischemia/reperfusion. Free Radic. Biol. Med.162, 339–352. 10.1016/j.freeradbiomed.2020.10.307

  • CrossRef
  • Google Scholar

• 237

  TarangeloA.MagtanongL.Bieging-RolettK. T.LiY.YeJ.AttardiL. D.et al (2018). p53 suppresses metabolic stress-induced ferroptosis in cancer cells. Cell Rep.22 (3), 569–575. 10.1016/j.celrep.2017.12.077

  • CrossRef
  • Google Scholar

• 238

  TevlinR.LongakerM. T.WanD. C. (2021). Deferoxamine to minimize fibrosis during radiation therapy. Adv. Wound Care11, 548–559. 10.1089/wound.2021.0021

  • CrossRef
  • Google Scholar

• 239

  ThomasC.MackeyM. M.DiazA. A.CoxD. P. (2009). Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles under oxidative stress: Implications for diseases associated with iron accumulation. Redox Rep.14 (3), 102–108. 10.1179/135100009X392566

  • CrossRef
  • Google Scholar

• 240

  ThurgurH.PinteauxE. (2019). Microglia in the neurovascular unit: Blood-brain barrier-microglia interactions after central nervous system disorders. Neuroscience405, 55–67. 10.1016/j.neuroscience.2018.06.046

  • CrossRef
  • Google Scholar

• 241

  TianQ.QinB.GuY.ZhouL.ChenS.ZhangS.et al (2020). ROS-mediated necroptosis is involved in iron overload-induced osteoblastic cell death. Oxid. Med. Cell. Longev.2020, 1295382. 10.1155/2020/1295382

  • CrossRef
  • Google Scholar

• 242

  TourkiB.BlackL. M.KainV.HaladeG. V. (2021). Lipoxygenase inhibitor ML351 dysregulated an innate inflammatory response leading to impaired cardiac repair in acute heart failure. Biomed. Pharmacother.139, 111574. 10.1016/j.biopha.2021.111574

  • CrossRef
  • Google Scholar

• 243

  TuoQ. Z.LeiP.JackmanK. A.LiX. L.XiongH.LiX. L.et al (2017). Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Mol. Psychiatry22 (11), 1520–1530. 10.1038/mp.2017.171

  • CrossRef
  • Google Scholar

• 244

  UrsiniF.MaiorinoM. (2020). Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic. Biol. Med.152, 175–185. 10.1016/j.freeradbiomed.2020.02.027

  • CrossRef
  • Google Scholar

• 245

  VarinA.GordonS. (2009). Alternative activation of macrophages: Immune function and cellular biology. Immunobiology214 (7), 630–641. 10.1016/j.imbio.2008.11.009

  • CrossRef
  • Google Scholar

• 246

  VerreyF.ClossE. I.WagnerC. A.PalacinM.EndouH.KanaiY. (2004). CATs and HATs: The SLC7 family of amino acid transporters. Pflugers Arch.447 (5), 532–542. 10.1007/s00424-003-1086-z

  • CrossRef
  • Google Scholar

• 247

  VespaP.PrinsM.Ronne-EngstromE.CaronM.ShalmonE.HovdaD. A.et al (1998). Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: A microdialysis study. J. Neurosurg.89 (6), 971–982. 10.3171/jns.1998.89.6.0971

  • CrossRef
  • Google Scholar

• 248

  Villalpando-RodriguezG. E.GibsonS. B. (2021). Reactive oxygen species (ROS) regulates different types of cell death by acting as a rheostat. Oxid. Med. Cell. Longev.2021, 9912436. 10.1155/2021/9912436

  • CrossRef
  • Google Scholar

• 249

  Waldvogel-AbramowskiS.WaeberG.GassnerC.BuserA.FreyB. M.FavratB.et al (2014). Physiology of iron metabolism. Transfus. Med. Hemother.41 (3), 213–221. 10.1159/000362888

  • CrossRef
  • Google Scholar

• 250

  WangY.DaiS. D.QiF. J.XuH. T.WangE. H. (2008). p53 protein expression and genetic mutation in two primary cell types in pulmonary sclerosing haemangioma. J. Clin. Pathol.61 (2), 192–196. 10.1136/jcp.2007.050401

  • CrossRef
  • Google Scholar

• 251

  WangH.ZhouW.ZhengZ.ZhangP.TuB.HeQ.et al (2012). The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage. DNA Repair (Amst)11 (2), 146–156. 10.1016/j.dnarep.2011.10.014

  • CrossRef
  • Google Scholar

• 252

  WangJ.SunZ.ShenJ.WuD.LiuF.YangR.et al (2015). Octreotide protects the mouse retina against ischemic reperfusion injury through regulation of antioxidation and activation of NF-κB. Oxid. Med. Cell. Longev.2015, 970156. 10.1155/2015/970156

  • CrossRef
  • Google Scholar

• 253

  WangZ.GuoL. M.WangY.ZhouH. K.WangS. C.ChenD.et al (2018). Inhibition of HSP90α protects cultured neurons from oxygen-glucose deprivation induced necroptosis by decreasing RIP3 expression. J. Cell. Physiol.233 (6), 4864–4884. 10.1002/jcp.26294

  • CrossRef
  • Google Scholar

• 254

  WangY.YangL.ZhangX.CuiW.LiuY.SunQ. R.et al (2019). Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep.20 (7), e47563. 10.15252/embr.201847563

  • CrossRef
  • Google Scholar

• 255

  WangH.LinD.YuQ.LiZ.LenahanC.DongY.et al (2021). A promising future of ferroptosis in tumor therapy. Front. Cell Dev. Biol.9, 629150. 10.3389/fcell.2021.629150

  • CrossRef
  • Google Scholar

• 256

  WangL.XiongX.ZhangL.ShenJ. (2021). Neurovascular unit: A critical role in ischemic stroke. CNS Neurosci. Ther.27 (1), 7–16. 10.1111/cns.13561

  • CrossRef
  • Google Scholar

• 257

  WardR. J.ZuccaF. A.DuynJ. H.CrichtonR. R.ZeccaL. (2014). The role of iron in brain ageing and neurodegenerative disorders. Lancet. Neurol.13 (10), 1045–1060. 10.1016/S1474-4422(14)70117-6

  • CrossRef
  • Google Scholar

• 258

  WatanabeK.TanakaM.YukiS.HiraiM.YamamotoY. (2018). How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?J. Clin. Biochem. Nutr.62 (1), 20–38. 10.3164/jcbn.17-62

  • CrossRef
  • Google Scholar

• 259

  WeiS.QiuT.WangN.YaoX.JiangL.JiaX.et al (2020). Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis. Environ. Res.188, 109824. 10.1016/j.envres.2020.109824

  • CrossRef
  • Google Scholar

• 260

  WillardS. S.KoochekpourS. (2013). Glutamate, glutamate receptors, and downstream signaling pathways. Int. J. Biol. Sci.9 (9), 948–959. 10.7150/ijbs.6426

  • CrossRef
  • Google Scholar

• 261

  WinklerE. A.BellR. D.ZlokovicB. V. (2011). Central nervous system pericytes in health and disease. Nat. Neurosci.14 (11), 1398–1405. 10.1038/nn.2946

  • CrossRef
  • Google Scholar

• 262

  WuJ.MinikesA. M.GaoM.BianH.LiY.StockwellB. R.et al (2019). Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling. Nature572 (7769), 402–406. 10.1038/s41586-019-1426-6

  • CrossRef
  • Google Scholar

• 263

  WuY.ZhangS.GongX.TamS.XiaoD.LiuS.et al (2020). The epigenetic regulators and metabolic changes in ferroptosis-associated cancer progression. Mol. Cancer19 (1), 39. 10.1186/s12943-020-01157-x

  • CrossRef
  • Google Scholar

• 264

  Wynford-ThomasD.BlaydesJ. (1998). The influence of cell context on the selection pressure for p53 mutation in human cancer. Carcinogenesis19 (1), 29–36. 10.1093/carcin/19.1.29

  • CrossRef
  • Google Scholar

• 265

  XieZ.XuM.XieJ.LiuT.XuX.GaoW.et al (2022). Inhibition of ferroptosis attenuates glutamate excitotoxicity and nuclear autophagy in a CLP septic mouse model. Shock57 (5), 694–702. 10.1097/SHK.0000000000001893

  • CrossRef
  • Google Scholar

• 266

  XuY.LiuY.LiK.YuanD.YangS.ZhouL.et al (2022). COX-2/PGE2 pathway inhibits the ferroptosis induced by cerebral ischemia reperfusion. Mol. Neurobiol.59 (3), 1619–1631. 10.1007/s12035-021-02706-1

  • CrossRef
  • Google Scholar

• 267

  YangW. S.KimK. J.GaschlerM. M.PatelM.ShchepinovM. S.StockwellB. R. (2016). Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl. Acad. Sci. U. S. A.113 (34), E4966–E4975. 10.1073/pnas.1603244113

  • CrossRef
  • Google Scholar

• 268

  YangS.JinH.ZhuY.WanY.OpokuE. N.ZhuL.et al (2017). Diverse functions and mechanisms of pericytes in ischemic stroke. Curr. Neuropharmacol.15 (6), 892–905. 10.2174/1570159X15666170112170226

  • CrossRef
  • Google Scholar

• 269

  YangQ.HuangQ.HuZ.TangX. (2019). Potential neuroprotective treatment of stroke: Targeting excitotoxicity, oxidative stress, and inflammation. Front. Neurosci.13, 1036. 10.3389/fnins.2019.01036

  • CrossRef
  • Google Scholar

• 270

  YangY.LuoM.ZhangK.ZhangJ.GaoT.ConnellD. O.et al (2020). Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma. Nat. Commun.11 (1), 433. 10.1038/s41467-020-14324-x

  • CrossRef
  • Google Scholar

• 271

  YangF.WuZ.DaiD.ZhangL.ZhangX.ZhangX.et al (2021). The iron chelator deferoxamine decreases myeloma cell survival. J. Int. Med. Res.49 (1), 300060520987396. 10.1177/0300060520987396

  • CrossRef
  • Google Scholar

• 272

  YeJ.SunZ.HuW. (2018). Roles of astrocytes in cerebral infarction and related therapeutic strategies. Zhejiang Da Xue Xue Bao Yi Xue Ban.47 (5), 493–498. 10.3785/j.issn.1008-9292.2018.10.08

  • CrossRef
  • Google Scholar

• 273

  YenariM. A.KauppinenT. M.SwansonR. A. (2010). Microglial activation in stroke: Therapeutic targets. Neurotherapeutics7 (4), 378–391. 10.1016/j.nurt.2010.07.005

  • CrossRef
  • Google Scholar

• 274

  YinH.XuL.PorterN. A. (2011). Free radical lipid peroxidation: Mechanisms and analysis. Chem. Rev.111 (10), 5944–5972. 10.1021/cr200084z

  • CrossRef
  • Google Scholar

• 275

  YuS. S.LiZ. Y.XuX. Z.YaoF.LuoY.LiuY. C.et al (2022). M1-type microglia can induce astrocytes to deposit chondroitin sulfate proteoglycan after spinal cord injury. Neural Regen. Res.17 (5), 1072–1079. 10.4103/1673-5374.324858

  • CrossRef
  • Google Scholar

• 276

  YuanH.LiX.ZhangX.KangR.TangD. (2016). Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun.478 (3), 1338–1343. 10.1016/j.bbrc.2016.08.124

  • CrossRef
  • Google Scholar

• 277

  YuanH.LiX.ZhangX.KangR.TangD. (2016). CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation. Biochem. Biophys. Res. Commun.478 (2), 838–844. 10.1016/j.bbrc.2016.08.034

  • CrossRef
  • Google Scholar

• 278

  ZhangD. D.LoS. C.CrossJ. V.TempletonD. J.HanninkM. (2004). Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol.24 (24), 10941–10953. 10.1128/MCB.24.24.10941-10953.2004

  • CrossRef
  • Google Scholar

• 279

  ZhangZ.ZhangF.AnP.GuoX.ShenY.TaoY.et al (2011). Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. Blood118 (7), 1912–1922. 10.1182/blood-2011-01-330324

  • CrossRef
  • Google Scholar

• 280

  ZhangZ.ZhangF.GuoX.AnP.TaoY.WangF. (2012). Ferroportin1 in hepatocytes and macrophages is required for the efficient mobilization of body iron stores in mice. Hepatology56 (3), 961–971. 10.1002/hep.25746

  • CrossRef
  • Google Scholar

• 281

  ZhangY.KoppulaP.GanB. (2019). Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell Cycle18 (8), 773–783. 10.1080/15384101.2019.1597506

  • CrossRef
  • Google Scholar

• 282

  ZhangC.YanL.GuZ.ZhaoY. (2019). Strategies based on metal-based nanoparticles for hypoxic-tumor radiotherapy. Chem. Sci.10 (29), 6932–6943. 10.1039/c9sc02107h

  • CrossRef
  • Google Scholar

• 283

  ZhangX.WangL.LiH.ZhangL.ZhengX.ChengW. (2020). Crosstalk between noncoding RNAs and ferroptosis: New dawn for overcoming cancer progression. Cell Death Dis.11 (7), 580. 10.1038/s41419-020-02772-8

  • CrossRef
  • Google Scholar

• 284

  ZhangX.SuiS.WangL.LiH.ZhangL.XuS.et al (2020). Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J. Cell. Physiol.235 (4), 3425–3437. 10.1002/jcp.29232

  • CrossRef
  • Google Scholar

• 285

  ZhangW.LiuY.ZhangH. (2021). Extracellular matrix: An important regulator of cell functions and skeletal muscle development. Cell Biosci.11 (1), 65. 10.1186/s13578-021-00579-4

  • CrossRef
  • Google Scholar

• 286

  ZhangY.LuX.TaiB.LiW.LiT. (2021). Ferroptosis and its multifaceted roles in cerebral stroke. Front. Cell. Neurosci.15, 615372. 10.3389/fncel.2021.615372

  • CrossRef
  • Google Scholar

• 287

  ZhangX.YuK.MaL.QianZ.TianX.MiaoY.et al (2021). Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. Theranostics11 (12), 5650–5674. 10.7150/thno.55482

  • CrossRef
  • Google Scholar

• 288

  ZhangH. L.HuB. X.LiZ. L.DuT.ShanJ. L.YeZ. P.et al (2022). PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis. Nat. Cell Biol.24 (1), 88–98. 10.1038/s41556-021-00818-3

  • CrossRef
  • Google Scholar

• 289

  ZhaoY.YangJ.LiC.ZhouG.WanH.DingZ.et al (2020). Role of the neurovascular unit in the process of cerebral ischemic injury. Pharmacol. Res.160, 105103. 10.1016/j.phrs.2020.105103

  • CrossRef
  • Google Scholar

• 290

  ZhaoY.LiY.ZhangR.WangF.WangT.JiaoY. (2020). The role of erastin in ferroptosis and its prospects in cancer therapy. Onco. Targets. Ther.13, 5429–5441. 10.2147/OTT.S254995

  • CrossRef
  • Google Scholar

• 291

  ZhaoQ.GeZ.FuS.WanS.ShiJ.WuY.et al (2022). DNA methylation plays an important role in iron-overloaded Tibetans. Genes Genet. Syst.97 (2), 55–66. 10.1266/ggs.21-00006

  • CrossRef
  • Google Scholar

• 292

  ZhouS.DuX.XieJ.WangJ. (2017). Interleukin-6 regulates iron-related proteins through c-Jun N-terminal kinase activation in BV2 microglial cell lines. PLoS One12 (7), e0180464. 10.1371/journal.pone.0180464

  • CrossRef
  • Google Scholar

• 293

  ZhouS.GaoB.SunC.BaiY.ChengD.ZhangY.et al (2020). Vascular endothelial cell-derived exosomes protect neural stem cells against ischemia/reperfusion injury. Neuroscience441, 184–196. 10.1016/j.neuroscience.2020.05.046

  • CrossRef
  • Google Scholar

• 294

  ZhouY.LiaoJ.MeiZ.LiuX.GeJ. (2021). Insight into crosstalk between ferroptosis and necroptosis: Novel therapeutics in ischemic stroke. Oxid. Med. Cell. Longev.2021, 9991001. 10.1155/2021/9991001

  • CrossRef
  • Google Scholar

• 295

  ZhouS. Y.GuoZ. N.ZhangD. H.QuY.JinH. (2022). The role of pericytes in ischemic stroke: Fom cellular functions to therapeutic targets. Front. Mol. Neurosci.15, 866700. 10.3389/fnmol.2022.866700

  • CrossRef
  • Google Scholar

• 296

  ZhouY.DanboltN. C. (2014). Glutamate as a neurotransmitter in the healthy brain. J. Neural Transm.121 (8), 799–817. 10.1007/s00702-014-1180-8

  • CrossRef
  • Google Scholar

• 297

  ZhuH.ItohK.YamamotoM.ZweierJ. L.LiY. (2005). Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: Protection against reactive oxygen and nitrogen species-induced cell injury. FEBS Lett.579 (14), 3029–3036. 10.1016/j.febslet.2005.04.058

  • CrossRef
  • Google Scholar

• 298

  ZhuS.ZhangQ.SunX.ZehH. J.LotzeM. T.KangR.et al (2017). HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res.77 (8), 2064–2077. 10.1158/0008-5472.CAN-16-1979

  • CrossRef
  • Google Scholar

• 299

  ZhuT.ShiL.YuC.DongY.QiuF.ShenL.et al (2019). Ferroptosis promotes photodynamic therapy: Supramolecular photosensitizer-inducer nanodrug for enhanced cancer treatment. Theranostics9 (11), 3293–3307. 10.7150/thno.32867

  • CrossRef
  • Google Scholar